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! Fish oil has immunosuppressive properties that could provide treatment for 
numerous inflammatory and autoimmune disorders. The primary bioactive components 
of fish oil, which are the n-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), can exert differential effects on many cell 
types in the body. A major limitation in the development of fish oil as a therapeutic is the 
lack of mechanistic understanding of how fish oil exerts its functional effects. One 
emerging mechanism is that EPA and DHA have unique biophysical properties that 
could disrupt the lateral organization of plasma membrane lipids and proteins critical for 
signaling and cell-cell communication, such as lipid rafts and the immunological 
synapse. In this study, we investigate a potential mechanism for this disruption in B 
cells, a cell type poorly represented in the field of n-3 PUFA research. The central 
hypothesis for this study was that fish oil disrupts lateral organization of lipid rafts and 
suppresses downstream B cell function. Using high and low fat fish oil diets in mice, we 
demonstrated that fish oil dispersed clustering of B cell lipid rafts on a micron scale, and 
enhanced membrane molecular order upon cross-linking raft domains. We found that 
the effects on lipid rafts are primarily driven by DHA and not EPA, and that n-3 PUFAs 
have a limited influence on non-raft lateral organization. Finally, we show that fish oil 
suppresses B cell antigen presentation and subsequent CD4+ T cell IL-2 secretion, by 
disrupting the B cell side of the immunological synapse. Taken together, this work 
highlights the utility of fish oil, more specifically DHA, as a tool for disrupting plasma 
membrane lateral organization. We add to the biochemical understanding of how these 
fatty acids may disrupt various downstream signaling events and cell-cell interactions. It 
also emphasizes the importance of the plasma membrane as a target for suppressing 
other cellular functions mediated through lipid raft domains. Finally, these studies add B 
cells as key targets for suppression of antigen presentation in diseases such as 
autoimmune disorders.
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CHAPTER 1: INTRODUCTION
Overview
! n-3 polyunsaturated fatty acids (PUFAs), also known as omega 3 fatty acids, are 
important bioactive molecules with many potential health benefits (1). In particular, 
consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the 
major n-3 PUFA bioactive components of fish oil, have been established as regulators of 
immune function (2). However, a major roadblock to widespread clinical utility of fish oil 
is the lack of clear understanding of the mechanisms for its beneficial effects. This 
dissertation addresses that limitation by investigating how incorporation of EPA and 
DHA into the plasma membrane modifies B cell function.
Historical perspective
! Research on n-3 PUFAs originated in the 1970s, when scientists began studying 
Greenland’s Inuit populations due to their incredibly low incidence of ischemic heart 
disease compared to the rest of the world (3). What they discovered was the Inuit 
population consumed a unique diet that led to decreased plasma lipid concentrations 
(4). Unlike most industrialized civilizations, this diet consisted of very high levels of n-3 
PUFAs from fish and other seafoods. The dietary n-3 PUFA levels amounted to around 
7% of total daily energy (5, 6). Some modern Japanese populations also have elevated 
n-3 PUFA intakes, especially when compared to the western diet, though not to the 
degree of the Greenland Inuits. The Japanese consume roughly 1-2% of daily energy 
from n-3 PUFA, which also correlates to moderate decrease in total mortality (7, 8). 
! Not until the 1990s and the early 2000s did increased awareness of the 
additional possible health benefits of consuming n-3 PUFAs become widespread. n-3 
PUFAs have been shown to be beneficial in a number of conditions such as 
cardiovascular disease (9-13), cancer (14-16), various inflammatory disorders (17-20), 
and cognitive health (21-23). A link between many of these conditions is the 
immunosuppressive properties of n-3 PUFAs (24). Therefore, this dissertation is 
focused on unveiling a mechanism for how fish oil suppresses immune cell function.
Biochemistry of n-3 PUFAs
! The unique structure of n-3 PUFAs is distinguished by multiple double bonds 
starting 3 carbons from the methyl end of the acyl chain. Similarly, n-6 PUFAs, a 
structurally related group of fatty acids, are distinguished by multiple double bonds 
starting 6 carbons from the methyl end. Animal tissues, unlike plants, are unable to 
synthesize either group of these fatty acids due to an inability to insert double bonds 
further than 9 carbons from the carboxyl end of the acyl chain (25). Once consumed 
through the diet, α-linolenic acid (ALA), 18:3 (n-3), or linoleic acid, 18:2 (n-6), can be 
converted into the longer chain PUFAs through a series of elongation and desaturation 
reactions (Figure 1.1). Retroconversion or β-oxidation of DHA can also generate EPA 
and docosapentaenoic acid (26). However, since ALA is at the top of this pathway, this 
makes ALA and linoleic acid essential dietary fatty acids. There are two major metabolic 
fates for ALA when consumed in the diet: 1) β-oxidation for use as a fuel source, 2) 
conversion into longer chain n-3 PUFAs for a variety of uses. Some studies suggest that 
most is used for β-oxidation (27, 28). In addition, the conversion of ALA to longer-chain 
n-3 PUFA is very inefficient, although the rate is slightly higher in pre-menopausal 
women (29). For instance, studies of plasma lipid levels in healthy individuals found that 
only 0.2% of radio-labeled ALA was able to be converted into EPA, whereas 63% of 
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3Figure 1.1: PUFA synthesis
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Figure 1.1: Polyunsaturated fatty acid (PUFA) synthesis. n-6 PUFA (left) and n-3 
PUFA (right) elongation pathways. Each step in either pathway uses the same 
enzymes.
EPA was able to be converted into DHA (30). This finding suggested that direct dietary 
consumption of EPA/DHA may be more beneficial for studying the effects of EPA/DHA 
than consumption of ALA alone. On the other hand, additional evidence suggests this 
limitation could be tissue dependent (31).
! An additional limitation of longer chain n-3 PUFA synthesis from ALA is the 
competition between the synthesis pathways of n-3 versus n-6 PUFAs. This competition 
is due to the fact that they share the elongase and desaturase enzymes for this process 
(32-34). Furthermore, animals are not able to convert an n-3 PUFA into an n-6 PUFA or 
vice versa. However, the C. elegans gene, fat-1, was identified for this process (35). 
Consequently, this discovery led to development of a transgenic mouse line where the 
fat-1 gene was expressed, resulting in abundant n-3 PUFA and reduced n-6 PUFA 
levels, without a dietary n-3 PUFA supply (36).
Recommended intake of n-3 PUFAs
! According to the American Heart Association, World Health Organization, and 
European Food Safety Agency, n-3 PUFAs should be added to the daily diet for good 
overall health and to prevent many diseases (37). The daily dietary recommended level 
of n-3 PUFAs has continually evolved, increasing as more information about their 
beneficial effects is gathered. Currently these organizations recommend healthy 
individuals consume on average 1 - 2.5 grams per day of total n-3 PUFA, including 200 
to 600 mg per day of EPA/DHA (37-40). Due to the limited conversion rate described 
above, and the evidence of the necessity of DHA for overall health, there has been a 
push to recognize DHA in addition to ALA as an essential dietary fatty acid (41, 42). 
These recommended levels can be achieved through a minimum of 2 servings of fish 
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per week, with one being oily fish (tuna, mackerel, salmon, or sardine). Consumption of 
fish does not come without some risks. Some contaminants in fish are methylmercury, 
dioxins, polychlorinated biphenyls, and organic pollutants from industrial processes. 
Advancement in dietary enrichment of milk, eggs, meat and other products with n-3 
PUFAs provides many new alternatives to fish consumption alone (43). In fact, market 
research by Packaged Facts predicts the n-3 PUFA food and beverage market, 
excluding fish, will become a $7 billion commercial industry by 2015 (44). 
! As supplements or food additives, n-3 PUFAs exist as two major forms, 
triglycerides or ethyl esters. The n-3 PUFAs present in fish or other oils are mostly in the 
triglyceride form. The triglyceride form seems to show increased efficiency in being 
absorbed through dietary intake compared to the ethyl ester form (45, 46). In both 
forms, the fatty acids are absorbed in the small intestine, cleaved by lipases, and 
reassembled into triglycerides. However, in the ethyl ester form, absorption and re-
synthesis is delayed, perhaps making this form less effective as a clinical treatment (47, 
48). Ethyl ester n-3 PUFAs can be re-esterified into a glycerol backbone during 
manufacturing, but this is usually not done because of the added costs. However, all 
forms seem to have similar abilities in treating hypertriglyceridemia (49, 50).
! Purified fish oil as ethyl esters has been clinically developed to lower elevated 
triglyceride levels with a drug called Lovaza. This is the only use for n-3 PUFAs that is 
clinically approved in the United States by the FDA, although the mechanism of action is 
still unclear. Four grams per day of EPA and DHA is prescribed for severe 
hypertriglyceridemia (≥500 mg/dL). This treatment represents approximately 465 mg of 
EPA and 375 mg of DHA per 1 g capsule of ethyl ester fatty acids. Lovaza is thought to 
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work by reducing triglyceride production and liver secretion, in addition to removing 
excess triglycerides from the blood (51). Both the types of n-3 PUFA and the dose used 
in many other therapeutic applications have varied widely, making it very difficult to 
make specific clinical recommendations for further applications (52). Fully elucidating 
the mechanisms remains a major theme of n-3 PUFA research. Specifically, this 
dissertation addresses that limitation by investigating how a specially formulated fish oil 
diet disrupts plasma membrane lateral organization and immunological function of B 
cells.
n-3 PUFAs and the immune system
! n-3 PUFAs have been extensively studied with regards to targeting immune cell 
function (53). Although there are many differential findings, common themes are that n-3 
PUFAs, specifically EPA/DHA, are immune system regulators. They assist in resolution 
of inflammation and act as immunosuppressants by regulating immune cell function (2, 
54, 55). The immune system, however, is layered in complexity, and n-3 PUFAs are 
thought to play a role in modifying many of its components. Immune cells are produced 
in bone marrow from multipotent progenitor cells, or hematopoietic stem cells, and 
migrate to the thymus, spleen, and lymph nodes, as well as many other organs. 
Multipotent hematopoietic stem cells further differentiate into either lymphoid progenitor 
or myeloid progenitor cells (56). Lymphoid progenitor cells will become B and T 
lymphocytes or natural killer cells (56). Myeloid progenitor cells develop to become 
monocytes, macrophages, basophils, neutrophils, erythrocytes, mast cells, and dendritic 
cells (56). These cell types make up the major cells of the immune system. The immune 
system can be broken down into two primary types of immune responses, which are the 
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innate response and the adaptive response. 
! Innate function is evolutionarily conserved and is the first line of defense against 
invading pathogens and other infectious agents. Inflammation plays a critical role in this 
process as a protective response to an injury or infection. The vascular and immune 
systems work together to respond to invasion of pathogens, irritants, or damaged cells 
by increasing blood flow and cell permeability to the affected area (57). Inflammation 
can be characterized as either acute or chronic. Resolving acute inflammation promptly 
is critical for overall health, as chronic inflammation is associated with a variety of 
diseases such as atherosclerosis, rheumatoid arthritis, metabolic syndrome, and some 
types of cancer (58). Cytokine release by damaged cells recruits immune cells. 
Phagocytic immune cells, such as macrophages, dendritic cells, and neutrophils, are 
recruited to the area to engulf and eliminate pathogens that could cause further 
infection. Some pathogens are recognized by pattern recognition receptors such as the 
Toll-like receptors (TLRs) (59). Phagocytized foreign pathogens are degraded, 
processed and various proteins are presented to cells of the adaptive immune system. 
This is a critical link between the two types of immune responses (60).
! The adaptive immune response can also be broken down into two parts: humoral 
and cellular. Humoral immunity is mediated primarily by B cell antibody secretion. Cell-
mediated immunity involves T cells activated by antigen presenting cells (APCs). The 
primary APCs are dendritic cells, but B cells and macrophages can also serve this 
function. Cell-mediated immunity involves direct contact through immunological 
synapses, described in detail below. Unlike the innate immune system, the adaptive 
immune system is designed to protect against many foreign contagions, and not just 
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specific evolutionarily conserved patterns. However, the two types of immune responses 
often work together to clear pathogens and maintain health.
! A number of studies have shown that n-3 PUFAs can be immunosuppressive by 
inhibiting proliferation of lymphocytes in both rodents and humans (24, 61-64). However, 
in some studies with human patients, conjugated linoleic acid was found to have limited 
results (65, 66). There is also evidence that cytokine secretion can be inhibited by n-3 
PUFA dietary supplementation. For example, secretion of pro-inflammatory cytokines IL 
(interleukin)-6 and TNF (Tumor necrosis factor)-α by macrophages was inhibited in rats 
(67). In dendritic cells, TNF-α and IL-12 cytokine secretion was diminished by n-3 
PUFAs (68). n-3 PUFAs have also been shown to suppress APCs ability to present 
antigen (69, 70). In addition, they have been shown to inhibit CD4+ T cell signaling and 
function (71, 72). Other studies suggest that the response between cell types may not 
be universally suppressive (73). However, B cells are a cell type poorly represented in 
the field of n-3 PUFA research. Therefore, a major focus of this work is on how n-3 
PUFAs modify B cell function.
B cells
! B cells are continually generated throughout the lifespan of most mammals. In 
the fetus, B cells differentiate in the liver. After birth, B cell generation moves to the bone 
marrow where they must undergo a differentiation and maturation process before 
becoming functioning members of the immune system (74). B cells leave the bone 
marrow and migrate through the periphery and into the lymphoid tissues of the lymph 
nodes and spleen. Currently there are ten known B cell–specific cell surface markers 
that have been identified: CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72, and 
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CD79a,b (75). The two major mature B cell subtypes are B-1 and B-2. B-1 cells are self-
renewing and long-lived. They are crucial for innate immune function in defense against 
encapsulated bacterial infections (76, 77). B-1 cells produce natural antibodies, which 
are secreted before an infection occurs. B-2 cells are the major adaptive immune 
response B cell type. There are two major splenic subpopulations, marginal zone and 
follicular cells. Marginal zone B cells mature from transitional type 1 and transitional 
type 2 precursors (78, 79) Marginal zone B cells are non-circulating and are also critical 
for defense against blood-borne encapsulated bacterial pathogens (79). Upon 
encountering an antigen, naïve mature follicular B cells process and present that 
antigen to cognate helper T cells in the periphery of a lymphoid follicle. The activated B 
cells become short-lived antibody secreting plasma cells, or migrate to a germinal 
center to rapidly proliferate and differentiate. In the germinal center, antibody affinity is 
refined through a process known as affinity maturation (80). The differentiated B cells 
then become long-lasting memory B cells that can rapidly proliferate and differentiate 
into plasma cells upon a second encounter with the same antigen (81). 
! While the primary role of B cells is antibody production, they are also recognized 
as important APCs for the initiation of immune responses (82-85). B cell MHC class II 
antigen presentation is critical for many autoimmune diseases like rheumatoid arthritis, 
lupus, allograft rejection, and chronic allergic lung disease (86-89). Suppression of B 
cell antigen presentation is a potential target for treatment of these disorders. For 
example, rituximab, a chimeric monoclonal antibody against CD20, suppresses B cell 
antigen presentation, which has some clinical benefits, especially in rheumatoid arthritis 
(90-93). B cells can also play a role in cytokine production, tumor immunity, cell 
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regulation, antiviral immunity, and wound healing (75, 94).
Potential mechanisms for n-3 PUFAs
! Consumption of n-3 PUFAs can affect nearly every cell in the body. In doing so, 
there are a variety of mechanisms that n-3 PUFAs can target. They can directly bind to 
receptors and modify gene regulation. For instance, n-3 PUFAs have been shown to 
bind peroxisome proliferator-activated receptors (PPARs) and liver x receptors (95, 96). 
In addition, there has been a recent discovery of a specific n-3 PUFA receptor, the G-
protein coupled receptor (GPR) 120 (97, 98). These studies with knockout mice 
demonstrated that GPR120 signaling plays a major role in obesity, inflammation, insulin 
resistance, and other symptoms of metabolic syndrome.
! n-3 and n-6 PUFAs also serve as precursors for pro- and anti-inflammatory 
metabolites. The discovery of these metabolites has established that the resolution of 
inflammation is not a passive process, but requires a variety of metabolites to activate 
inflammatory pathways, followed by further synthesis of pro-resolving mediators to 
resolve the inflammation once the process is complete (99-101). These pro-
inflammatory molecules are primarily the n-6 PUFA arachidonic acid (AA) derived 
eicosanoids, made up of leukotrienes, prostaglandins, thromboxanes, and 
prostacyclins. However, EPA competes for enzyme activity with AA, limiting the AA 
production pathway and promoting alternative EPA derived eicosanoid production (102). 
The eicosanoids derived from EPA have weaker pro-inflammatory bioactivity than AA 
derived products (103). EPA and DHA also serve as precursors for the potent 
inflammation-resolving molecules known as E or D series resolvins, protectins/
neuroprotectins and, more recently, maresins. (104). After an inflammatory response, 
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these resolvins/protectins promote resolution of inflammation through removal of 
leukocytes (104).
! n-3 PUFAs also have unique structural properties. They can be esterified at the 
sn-2 position of phospholipids. As a phospholipid constituent, it has been shown that 
DHA can cause significant alteration to fluidity and permeability, as well as surrounding 
membrane protein function (105). Molecular dynamic simulations have shown that DHA 
acyl chains have an unusually high degree of conformational flexibility in membranes 
compared to other acyl chains (106). It is therefore proposed that DHA modifies plasma 
membrane order by disrupting hydrogen bonding between surrounding acyl chains and 
cholesterol (105). This results in an incompatibility between the rigid structure of 
cholesterol and DHA. In addition, DHA is thought to form DHA rich domains that are 
segregated from cholesterol rich membrane domains (107). These cholesterol rich 
membrane domains, known as lipid rafts, have critical functions for many cellular 
processes. Defining how dietary n-3 PUFAs disrupt lateral organization of lipid rafts in B 
cells is one of the primary aims for this dissertation.
Lipid rafts
! Our understanding of the complexities of the plasma membrane has advanced 
greatly since the establishment of the fluid mosaic model in the 1970‘s by Singer and 
Nicolson (108). We now have evidence for non-random associations of proteins and 
lipids in functional membrane domains of various sizes and functions (109). Lipid rafts 
are membrane domains of recent importance (110). Highly ordered in nature, they are 
defined as sphingolipid and cholesterol-rich domains. They are heterogeneous in 
composition but small in size, roughly 10 - 200 nm in diameter (111). Functionally, lipid 
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rafts are thought to compartmentalize important cell signaling events by serving as 
platforms for protein clustering (110, 112, 113). 
! Despite extensive characterization of lipid raft components and properties, there 
remains controversy associated with the existence of in vivo lipid raft domains (114, 
115). Much of this controversy lies in the methods used to isolate or image these 
membrane domains (116-118). Many of the early studies relied on insolubility in mild 
detergent followed by density centrifugation, but this method is now highly debated 
because of the potential for artifacts (119). Furthermore, detergent methods 
homogenize lipid raft components and give no information about how they were 
distributed in an intact plasma membrane. 
! Progress in fluorescence microscopy has allowed for limited visualization of 
these elusive domains by fluorescently tagging raft-associated proteins identified by the 
detergent extraction studies (120, 121). One such raft constituent, the ganglioside 
GM-1, binds the non-lethal subunit of cholera toxin (CTx-B) and is commonly used for 
imaging lipid rafts (122). This protein is readily available as a kit, with a variety of 
fluorescent proteins. The CTx-B proteins are then cross-linked by antibodies to 
aggregate larger lipid raft clusters that are now visible on the micron scale. However, a 
limitation to this application is that the CTx-B/antibody kit induces raft formation, and the 
natural in vivo state may not be represented by this method. Other studies use 
quantitative microscopy techniques such as Förster resonance energy transfer (FRET) 
to obtain nanoscale spatial information about components of rafts, and attempt to 
visualize these domains with minimal disruption. FRET can detect changes in protein 
distribution less than 10 nm apart, the size scale in which lipid raft protein clustering 
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occurs. FRET measures non-radiative energy transfer from a donor fluorophore on one 
protein to that of an acceptor on another closeby protein (117). One such study found 
evidence for highly dynamic nanoclusters of GPI-linked proteins using FRET (123). 
Further advances in super resolution microscopy like stimulated emission depletion 
(STED), stochastic optical reconstruction microscopy (STORM), and fluorescence 
photoactivation localization microscopy (fPALM) have revealed dynamic nanoscale 
lipodomains in living cells (124). Recently, advanced single-molecule fluorescent 
tracking methods were used to study the lateral organization of 
glycosylphosphatidylinositol-anchored (GPI) proteins in rafts (125). Suzuki et al. found 
homodimer formation of GPI proteins may be a critical mechanism for raft assembly 
(125). Further advances in studying lipid rafts will enhance understanding of numerous 
cellular processes because of the diversity of signaling pathways that utilize lipid rafts.
! As mentioned above, DHA has a low affinity for cholesterol due to steric 
incompatibility (126). This property makes DHA, and likewise other n-3 PUFAs, a 
potential disrupter of lipid rafts. Subsequently it has been shown that n-3 PUFAs do 
affect cell signaling by altering lipid raft domains (127-129). However, most n-3 PUFAs 
actually end up in non-raft domains. Therefore, there are also implications to protein 
organization in non-raft domains (130). This dissertation further investigates the 
mechanism of how dietary n-3 PUFAs disrupt plasma membrane lateral organization in 
B cells.
The immunological synapse
! In APCs such as B cells, direct cell-cell communication and subsequent 
activation can occur through contact between complementary regions of the plasma 
13
membrane on B and T cells. This contact region is defined as the immunological 
synapse, and its formation is thought to be dependent on lipid rafts (131). APCs use 
major histocompatibility complex (MHC) proteins on the plasma membrane surface to 
present antigens to T cells. The antigen-loaded complex is recognized and bound by the 
T cell receptor (TCR). This contact, along with a host of other proteins, constitutes the 
immunological synapse. The immunological synapse can be further defined as a 
supramolecular activation cluster (SMAC), which consists of central, peripheral, and 
distal regions. The complex is actively assembled and matures over time (132). Initially, 
MHC class II, found on B cells, is bound to TCR and gradually clustered to the central 
SMAC (c-SMAC), along with other proteins such as protein kinase Cθ (PKCθ), CD2, 
CD4, CD8, CD28, Lck, and Fyn (132). Cytoskeletal elements such as talin and actin 
surround this central region in the peripheral SMAC (p-SMAC), driving other proteins 
toward the c-SMAC (133). The functional anatomy of some of the elements involved in 
this contact region is depicted in Figure 1.2. 
! At high antigen levels synapse formation initiates very quickly and maturation 
occurs over as much as 6 hours (134). First the APC and T cell scan the surface to find 
complementary TCR and MHC class II molecules, respectively. In order to check 
antigen specificity, T cells also undergo a form of kinetic proofreading, similar to 
mechanisms in DNA synthesis (135). During this process, phosphorylation events 
pause signal transduction after antigen recognition to discriminate self and foreign 
antigens (135). This greatly enhances the receptor's ability to discriminate between a 
foreign antigen and self-antigens and ensures incorrect signals are not processed. 
When antigen levels are low or TCR affinity to antigen is low, many TCRs are triggered 
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Figure 1.2: The B-T cell immunological synapse. Shown in blue (top) is the B side of 
the immunological synapse. In green (bottom) is the T cell side. B proteins MHC class II 
and CD80, as well as T cell proteins TCR, CD28, and CD4 cluster in the cSMAC shown 
in yellow. Adhesion molecules, ICAM1 and LFA-1, cluster in the pSMAC, which 
surrounds the cSMAC.
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Figure 1.2
sequentially through a process called serial triggering to resolve the lower affinity (136). 
Once the antigen is recognized and verified, calcium signaling and synapse assembly 
begins immediately. After initial APC contact with a T cell, signaling can begin at as early  
as 45 seconds. However, full maturation and T cell activation requires SMAC formation 
(137). As the synapse matures over the course of 5-60 minutes, SMAC formation and 
segregation occurs. Some evidence shows that although dendritic cells are professional 
APCs, full synapse maturation does not occur in these cells (138). Finally, after a few 
hours when signaling is complete, the TCR internalizes and the synapse is dissolved.
! The immunological synapse is a potential target for n-3 PUFAs as a mechanism 
for their immunosuppressive properties (71, 139). Dietary n-3 PUFAs are known to 
suppress recruitment of PKCθ, as well as other structural proteins, to the site of the 
immunological synapse in CD4+ T cells by increasing lipid raft formation (140). Dietary 
n-3 PUFAs also limit mitochondrial translocation to the immunological synapse in T 
cells, an early step in T cell activation (141). Additionally, studies in other immune cell 
types yield similar lipid raft disruption and impaired function (142, 143). Much less is 
known, however, about B cells. B cells have a critical function in antibody production, 
but, like dendritic cells, they also are involved in activating T cells through the 
immunological synapse. Therefore, the goal of this dissertation is to describe how EPA 
and/or DHA can target lipid rafts in B cells, thereby disrupting antigen presentation.
Specific aims
! n-3 PUFAs are the primary bioactive components of fish oil. Consumption of fish 
oil can elicit immunosuppressive effects, as well as many other potential health benefits. 
However, a limitation in the clinical utility of n-3 PUFAs is the lack of understanding of 
16
how they exert their effects. To address this limitation, we investigated a potential 
mechanism for how n-3 PUFAs suppress B cell immune function. The central 
hypothesis was that n-3 PUFAs disrupt lipid rafts, as well as the direct contact of plasma 
membrane regions between B cells and T cells in the immunological synapse, thereby 
suppressing B cell function. This study serves to aid in potential treatment for chronic 
inflammatory and autoimmune disorders where immunosuppression of B cell antigen 
presentation by n-3 PUFAs would be beneficial (86-89). To address the central 
hypothesis, the specific aims are:
Aim 1: Test the hypothesis that dietary n-3 PUFAs disrupt B cell lipid raft 
organization and function.
! Proteins important for B cell function localize to lipid rafts where they can cluster 
for signal transduction. Disruption of protein and lipid lateral organization in lipid rafts 
could lead to modification of B cell function. To investigate the hypothesis that dietary 
n-3 PUFAs disrupt lipid raft organization, we first identified how n-3 PUFAs incorporate 
into the plasma membrane. We then determined the types of phospholipids into which 
dietary n-3 PUFAs incorporate. Using various fluorescent probes, we determined how 
high and low fat n-3 PUFA diets modified raft and non-raft biophysical properties. 
Finally, we measured the effect of fish oil on micron and nanoscale clustering of lipid raft 
localized functional proteins vital to immunological synapse formation. 
Aim 2: Test the hypothesis that n-3 PUFA diet modified B cells diminish stable 
immunological synapse formation.
! The immunological synapse is structurally organized into cSMAC- and pSMAC-
containing antigen receptors and adhesion molecules. Disruption of this structure in T 
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cells by n-3 PUFAs has been shown. Here we tested the functional consequences of 
dietary modifications on B cell plasma membranes by n-3 PUFAs. In doing so, we 
tested the hypothesis that B cells from n-3 PUFA fed mice would inhibit the formation of 
the immunological synapse, and therefore suppress T cell activation. We first measured 
the effect n-3 PUFAs have on the kinetics of initial immunological synapse or conjugate 
formation. We then directly imaged the immunological synapse using confocal 
microscopy to determine how n-3 PUFA dietary modification of B cells modified lateral 
organization of key T cell proteins. Finally, we determined the functional outcomes of 
dietary B cell modification on CD4+ T cell activation efficiency. 
! Taken together, this study defines a mechanism through which n-3 PUFAs modify 
B cell function and regulate immunological synapse formation. In addition, we 
characterized various n-3 PUFA rich diets and some of the metabolic implications of 
consuming very high doses of these unique fatty acids. We also further established that 
relevant dietary doses of fish oil can modify lipid raft organization in B cells as well as 
immunological synapse formation. This study will aid in the clinical application of n-3 
PUFAs as immunosuppressants.
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CHAPTER 2: MEMBRANE RAFT ORGANIZATION IS MORE SENSITIVE TO 
DISRUPTION BY N-3 PUFA THAN NONRAFT ORGANIZATION IN EL4 AND B CELLS1
Introduction
! EPA and DHA, the bioactive n-3 PUFA of fish oil, are increasingly available and 
consumed by the general public as over-the-counter supplements (43, 144). Clinically, 
EPA and DHA have applications for the prevention and/or treatment of some metabolic 
diseases (50, 145-147); in addition, they have potential utility for treating the symptoms 
associated with inflammatory and autoimmune disorders (2, 54, 148). However, one 
major limitation of further developing these fatty acids for clinical use is an incomplete 
understanding of their targets and molecular mechanisms.
! An emerging mechanism of the action of n-3 PUFA, due to their unique molecular 
structure, is modification of plasma membrane lipid rafts (149), which are sphingolipid-
cholesterol enriched domains that compartmentalize signaling proteins (124). We 
recently discovered an n-3 PUFA disrupted lipid raft clustering of EL4 cells (150). The 
data raised a new question, i.e. could n-3 PUFA also disrupt the organization of nonraft 
domains. These membrane domains are broadly defined as those regions that are not 
enriched in sphingolipids and cholesterol that also compartmentalize specific proteins 
(e.g. MHC class I, TLR4, etc.) (151). There were 2 reasons to hypothesize n-3 PUFA 
would disrupt nonraft organization. First, experiments using model membranes 
demonstrated DHA acyl chains, due to their structural incompatibility with cholesterol, 
primarily incorporated into nonrafts to enhance nonraft formation (130, 152, 153). 
1This research was originally published in The Journal of Nutrition. Rockett, B. D., 
Franklin, A., Harris, M., Teague, H., Rockett, A., & Shaikh, S. R. Membrane raft 
organization is more sensitive to disruption by (n-3) PUFA than nonraft organization in 
EL4 and B Cells. J Nutr. 2011; 141:1041–1048. © the American Society for Nutrition.
Second, biochemical detergent extraction studies showed a large fraction (up to 70%) of 
EPA and DHA localized into nonrafts (150, 154-156). Thus, these studies suggest that a 
major role of n-3 PUFA acyl chains is to modify nonraft domain organization.
! The first objective of this study was to extend our previous work by determining if 
EPA and DHA treatment disrupted nonraft organization of EL4 cells. The second 
objective was to translate the findings on EL4 cells by testing the impact of dietary n-3 
PUFA on both nonraft and lipid raft organization in an animal model. To address our 
objectives, we relied on quantitative imaging methods of confocal and FRET 
microscopy. Application of these methods to the study of n-3 PUFA and membrane 
domains advances the field by overcoming the use of cold detergent extraction as a 
primary method of studying how n-3 PUFA modify membrane domains. Although 
detergent resistance has great predictive value, the detergent can induce artifacts 
(157-159). Furthermore, the biochemical detergent method does not report on the 
effects of n-3 PUFA on the appropriate length scales on which membrane domains form 
(124). Therefore, we used more appropriate imaging methods to address the effects of 
n-3 PUFA on membrane domain organization.
Materials and Methods
Cells
! EL4 cells were maintained in RPMI 1640–1× (Mediatech) with 10% heat-
inactivated defined FBS (Hyclone), 2 mmol/L L-glutamine (Mediatech), and 1% 
penicillin/streptomycin (Mediatech) at 37°C in a 5% CO2 incubator. The lipid composition 
of the FBS was as previously reported (150).
Fatty acid treatment
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! A total of 9–10 × 105 EL4 cells was treated for 15.5 h with 25 µmol/L FFA (free 
fatty acid, Nu-Check Prep) complexed to fatty acid-free BSA (Bovine serum albumin, 
Roche Biochemicals) in serum-free medium as previously described (150). For select 
experiments, EL4 cells were treated in the presence of 10% FBS. The rationale for 
selecting the fatty acid concentration and time of treatment was to be consistent with 
our previous study on EL4 cells and membrane domains (150). Oleic (OA) and AA were 
tested to rule out general effects of fatty acid treatment and to ensure specificity of EPA 
and DHA.
Mice, diets, and B cell isolation
! Male C57BL/6 mice (Charles River), aged 4–6 wk (~18 g), were fed the following 
diets (Harlan-Teklad) for 3 wk: a purified control diet (CD) (5% fat wt:wt), a n-6 PUFA 
diet (20% fat wt:wt), a low-fat (LF) n-3 PUFA diet (5% fat wt:wt), or a high fat (HF) n-3 
PUFA diet (20% fat wt:wt) (Table 2.1) (160, 161). For the CD and LF n-3 PUFA diets, 
~13% of the total energy was from fat. For the HF n-6 and n-3 PUFA diets, ~41% of the 
total energy was from fat. For the LF n-3 PUFA diet, 3.3% of the total energy was from 
α-linolenic acid, 1% from EPA, and 0.6% from DHA (160). For the HF n-3 PUFA diet, 
10.5% of the total energy was from α-linolenic acid, 3% from EPA, and 2% from DHA 
(160). The diets were analyzed for their fatty acid composition (Supplemental Table 2.1). 
For B cell isolation, mice were killed using CO2 inhalation after 3 wk of feeding. Naïve 
B220+ B cells (>90% purity) from splenocytes were purified with negative selection 
(Miltenyi Biotec) as previously described (160). All experiments with mice fulfilled 
guidelines established by the East Carolina University for euthanasia and humane 
treatment.
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Table 2.1: Composition of experimental diets
Ingredients (g/kg) CD HF (n-6) PUFA LF (n-3) PUFA HF (n-3) PUFA 
Casein 185.0 220.0 185.0 220.0
L-Cystine 2.5 3.0 2.5 3.0
Corn starch 370.0 173.9 370.0 173.9
Maltodextrin 140.0 140.0 140.0 140.0
Sucrose 150.0 150.0 150.0 150.0
Cellulose (fiber) 50.0 50.0 50.0 50.0
Flaxseed oil 0.0 0.0 23.1 92.5
Fish oil (Menhaden) 0.0 0.0 23.1 92.5
Soybean oil 50.0 30.0 3.75 15.0
Safflower oil 0.0 125.0 0.0 0.0
Hydrogenated coconut oil 0.0 45.0 0.0 0.0
Mineral mix, AIN-93M2 35.0 42.0 35.0 42.0
Vitamin mix, AIN-932 15.0 18.0 15.0 18.0
Choline bitartate 2.5 3.0 2.5 3.0
TBHQ 0.02 0.06 0.02 0.06
C57BL/6 mice were fed for 3 weeks CD, HF (n-6) PUFA, LF and HF (n-3) PUFA diets. 
Composition of mineral and vitamin formulas are as reported in (161).
22
Fatty acid analysis
! For analysis of diets, ∼0.01–0.05 g of the diet pellets was homogenized using a 
Dounce homogenizer prior to extraction. Total lipids were extracted and analyzed 
relative to standards (Restek) from the differing cell types or diets with gas 
chromatography (GC) using our previously published protocol (150, 160). Areas of 
identified peaks were summed and each peak area is expressed as the percentage of 
total peak area for a given treatment (150, 160).
Column chromatography
! To assess incorporation of EPA and DHA into neutral lipid, FFA, and polar lipid 
fractions, 2 × 106 EL4 cells were treated with fatty acids spiked with 185 kBq [14C]EPA 
or [14C]DHA (American Radiolabeled Chemicals). Extracted lipids were separated into 
different lipid classes using aminopropyl beads (Sigma) loaded in a Pasteur pipette with 
a fiberglass plug and elution with HPLC-grade organic solvents (Fisher Scientific) as 
previously described (160, 162).
Staining and imaging with 1,19-dilinoleyl-3,3,39,39-tetramethylin-docarbocyanine 
perchlorate and 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
hexadecanoic acid
! A total of 2 × 106 cells was washed twice with cold PBS, stained with 0.66 mg/L 
of the nonraft probe 1,1′-dilinoleyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate 
(FAST-DiI; Invitrogen) or 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
hexadecanoic acid (C16-Bodipy; Invitrogen) for 5 min on ice followed by 2 washes with 
cold PBS (163, 164). Cells were fixed in 4% paraformaldehyde (Fisher Scientific) for 1 
h, washed twice, placed in Vitrotubes (Fiber Optic Center), and mounted onto slides 
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with nail polish. All imaging studies, described below, relied on a Zeiss LSM510 confocal 
microscope using a 100× oil objective. Pinhole, detector gain, and laser settings were 
kept constant between samples for a given experiment. For some experiments, images 
were acquired as z-stacks.
Sample preparation for FRET microscopy
! MHC class I molecules were used as the probe to measure nanometer scale 
molecular proximity, because these molecules are localized to nonrafts and are 
established to serve as excellent reporters for measuring changes in membrane 
organization (165-167). Cells were stained with varying concentrations of Cy3 (donor) 
and Cy5 (acceptor) separately labeled M1/42.3.9.8 anti-MHC class I antibodies 
(BioXCell). Fluorophores were conjugated to the antibody using a standard fluorophore 
conjugation kit (GE Healthcare). Specificity of the antibody was confirmed by using 
isotype controls (BioXCell) (150). Total antibody levels were held constant at 0.02 mg/
sample using unlabeled antibody as donor:acceptor ratios were varied from 1:1, 1:2, 
and 1:3 in 1 × 10−4 L PBS (168, 169). Cells were stained for 15 min on ice, washed 
twice with PBS, fixed, washed, and mounted to slides as described above. A positive 
control M1/42.3.9.8 antibody was generated by simultaneously conjugating Cy3 and 
Cy5 fluorophores, yielding a dual labeled antibody to ensure high FRET. Negative 
control samples were labeled with donor fluorophore only to check for donor channel 
bleaching during acceptor fluorophore bleaching and acceptor fluorophore only to 
optimize bleaching time.
FRET microscopy
! FRET was measured in terms of the efficiency of energy transfer (E) from donor 
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(Cy3) to acceptor (Cy5) fluorophores separated by distance r, given by the following 
equation: E = 1/{1 + (r/Ro)6}, where Ro is the Förster radius of the donor and acceptor 
fluorophore pairs and is 54 Å for Cy3/Cy5 (170, 171). The filter sets were 560- to 615-
nm band pass for Cy3, and 650-nm long pass for Cy5 in 2 separate tracks. Excitation 
relied on 543- and 633-nm lasers, respectively, for Cy3 and Cy5. Eight-bit 512 × 512 
pixel images were acquired. Acceptor photobleaching was carried out by iterative 
scanning of the 633-nm laser for ~2 min. Gain settings were optimized to ensure images 
were not saturated after photobleaching.
Lipid raft staining
! B cells were labeled with cholera toxin subunit B-FITC (Invitrogen) for cross-
linking lipid rafts and imaged as previously described (150).
Image analysis
! All images were analyzed with NIH ImageJ. Approximately 20–33 cells per 
treatment per experiment were analyzed as previously described (150). For FAST-DiI 
and C16-Bodipy studies, differential interference contrast images were routinely used to 
confirm plasma membrane compared with intracellular staining. For image intensity 
analysis, images were background subtracted and manually thresholded for regions of 
interest either inside the cell or on the plasma membrane. The approach was confirmed 
by selecting several regions of interest manually drawn on the cell surface and inside 
the cell. Cells were also scored as high intensity if they were in the top one-third of the 
distribution of fluorescence intensities.
! FRET images were analyzed with FRETcalc v3.0 plug-in for NIH ImageJ (172). 
Some cells could not be properly registered and were not included in the analysis. 
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Images were registered by manual translation or rotation. All images were background 
subtracted and smoothed using a 3 × 3 filter. The threshold values for the donor and 
acceptor images were determined manually. This was required to calculate FRET 
efficiency of the entire cell by the FRETcalc plug-in (172).
! Images of lipid rafts were background subtracted and raft size was determined in 
terms of Feret diameter using NIH ImageJ as previously described (150).
Cell growth and apoptosis measurements
! Cell growth was determined by counting cells in duplicate or triplicate using a 
hemacytometer. Dead cells were excluded with Trypan blue (HyClone, Fisher Scientific) 
staining. Measurements were routinely confirmed by a second person using blinded 
samples. We verified that this approach gave the same results as a cell proliferation 
testing kit (GenScript). The advantage of counting cells over the kit was the absolute 
number of cells could be determined rather than relative changes. Cell survival was 
measured in terms of Annexin V-Cy5/Sytox Blue (BD Pharmingen) staining with a BD 
LSR II flow cytometer as previously described (160).
Statistical analysis
! Reported values are means ± SEM from several independent experiments. For 
animal studies, independent experiments were conducted using 1 mouse from each diet 
group. All statistical analyses were conducted using Excel and GraphPad Prism 
(GraphPad Software). Parametric statistics were used, because the data were normally 
distributed. Unequal variances were tested for prior to ANOVA using a Levene’s test. 
For FRET studies, efficiency values varied between experiments due to variation in the 
fluorophore to antibody ratios; thus, significance was established against the control 
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using repeated-measures 1-way ANOVA followed by a Dunnett’s t test. For cell growth 
and apoptosis measurements as a function of time, 2-way ANOVA analysis was used 
followed by a Bonferroni t test. The 2-way ANOVA used treatment and time as factors 
and there was no interaction effect. For all other studies, significance was established 
against the control using a 1-way ANOVA followed by a Dunnett’s t test. P-values < 0.05 
were considered significant.
Results
EPA and DHA treatment disrupted nonraft organization of EL4 cells
! EPA and DHA treatment of EL4 cells increased accumulation of the nonraft probe 
FAST-DiI in the plasma membrane by ~50–70% relative to the BSA control (Figure 
2.1A,B). The OA and AA treatments did not significantly increase FAST-DiI uptake 
compared with BSA (Figure 2.1B). The intensity of FAST-DiI inside of the cell was not 
changed by treatment with any of the fatty acids (Figure 2.1B). The increase in FAST-DiI 
plasma membrane binding with EPA and DHA was also confirmed by scoring the cells 
for intensity. EPA and DHA treatment resulted in the largest percentage of cells with a 
high intensity of plasma membrane staining compared with BSA (Figure 2.1C).
! A major concern was that the EPA and DHA treatment exerted a general effect on 
fluorescent probe uptake. Therefore, we tested the effects of fatty acid treatment on the 
uptake of a nonspecific probe, C16-Bodipy (173). C16-Bodipy did not merely report on 
the same subcellular organization as FAST-DiI. Colocalization analysis of z-stacks of 
EL4 cells costained with FAST-DiI and C16-Bodipy showed the percent colocalization 
between the 2 probes was ~32%, as measured by Mander’s coefficients (Supplemental 
Figure 2.1A) (150). Relative to BSA, EPA and DHA treatment did not promote uptake of 
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Figure 2.1: EPA and DHA treatment disrupted nonraft organization of EL4 cells. 
(A) Fluorescence images of EL4 cells treated with BSA, OA, AA, EPA, or DHA and 
stained with FAST-DiI. (B) FAST-DiI intracellular and plasma membrane image intensity. 
(C) Percentage of cells with high FAST-DiI intensity as a function of treatment. (D) 
Sample images of BSA-treated cells from acceptor photobleaching FRET. (E) FRET 
efficiency values for treated EL4 cells. Images are on a rainbow palette to discriminate 
differences in relative fluorescence intensity. Red and blue values indicate high and low 
intensity, respectively. Data are means ± SEM, n = 3–4. Data in E are from 60-90 total 
cells analyzed. Asterisks indicate different from BSA: *P < 0.05, **P < 0.01, ***P < 
0.001. Data in A-B were collected by Franklin, A.
C16-Bodipy into the plasma membrane or inside the cell (Supplemental Figure 2.1B). 
OA and AA treatments also had no effect.
! We also determined if EPA and DHA treatment modified nonraft organization on a 
nanometer scale using FRET microscopy. Positive control experiments showed the 
acceptor photobleaching approach with Cy3 and Cy5 antibodies increased FRET 
(Supplemental Figure 2.2A). The distribution of MHC class I molecules on the surface of 
EL4 cells was then determined as random, clustered, or a mixture of random and 
clustered by increasing the donor:acceptor fluorophore ratios. FRET efficiency did not 
increase with increasing donor:acceptor ratios (Supplemental Figure 2.2B), which is the 
signature pattern of a random distribution of molecules (168, 169). This allowed us to 
combine FRET acceptor:donor ratios in the subsequent analyses.
! Analysis of FRET efficiency values from FRET images (Figure 2.1D) in every 
single experiment showed EPA and DHA treatment consistently decreased FRET by 
25–30% relative to the BSA control (Figure 2.1E). OA and AA treatments did not lower 
FRET relative to BSA. The most plausible explanation for an increase in the distance 
between neighboring MHC I molecules with n-3 PUFA was an increase in cell size, 
which was investigated next.
EPA and DHA treatment increased cell size and growth
! Cell size was measured in terms of forward scatter with flow cytometry (Figure 
2.2A). EPA and DHA treatment increased cell size by ~26% relative to BSA after 15.5 h 
of treatment. OA and AA treatment had no effect. A similar trend was confirmed with 
microscopy measurements (data not shown). EPA and DHA, in addition to AA, 
treatment also increased side scatter relative to BSA (data not shown).
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Figure 2.2: EPA and DHA treatment increased EL4 cell size and growth and 
prevented cell death. (A) Median forward scatter values for EL4 cells treated with BSA, 
OA, AA, EPA, or DHA. (B) Cell growth, (C) early apoptosis, and (D) late apoptosis as a 
function of time for the different treatment groups. Data are means 6 SEM, n = 4. 
Asterisks indicate different from BSA: *P < 0.05, **P < 0.01, ***P < 0.001.
! The subsequent experiment tested if the increase in cell size related to a change 
in cell growth (Figure 2.2B). At 15.5 h of treatment, cell number between the BSA 
control and the differing fatty acids did not differ. After 24 h, EPA and DHA treatment 
increased the number of viable cells. In contrast, OA and AA treatment did not increase 
cell growth compared with BSA. We then tested if the increased ability to grow was 
driven by an ability to prevent cell death. At 15.5 h of treatment, the cells were equally 
viable when measured for early and late apoptosis (Figure 2.2C,D) (150). After 24 h of 
treatment, all 3 PUFA (AA, EPA, and DHA) prevented early and late apoptosis relative 
to the BSA control (Figure 2.2C,D). OA treatment had no effect relative to BSA.
EPA and DHA treatment did not modify nonraft organization when cell size was 
unchanged.
! We determined if preventing the expansion of cell size prevented changes in 
nonraft organization. Treatment conditions were first optimized to prevent an increase in 
cell size but still allowed for efficient uptake of the fatty acids. Cells were treated in the 
presence of 10% FBS, which significantly elevated EPA and DHA levels (Figure 2.3A). 
Uptake of EPA and DHA into polar lipids did not change relative to treatment in serum 
free conditions, as measured with radiolabeled fatty acids (Figure 2.3B). Forward 
scatter values did not differ between EPA and DHA treatment compared with the BSA 
control (data not shown). Image analysis of cells stained with FAST-DiI (Figure 2.3C) 
showed no change in fluorescence intensity with EPA- or DHA-treated cells relative to 
BSA. Similarly, subsequent FRET imaging showed treatment of EL4 cells with n-3 
PUFA did not lower FRET relative to BSA. FRET efficiency values were ~10% for BSA-, 
EPA-, and DHA-treated cells.
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Figure 2.3: EPA and DHA treatment had no effect on nonraft organization when 
cell size was unchanged. (A) Total levels of 20:4, 20:5, 22:5, and 22:6 upon treatment 
of EL4 cells with BSA, EPA, or DHA in serum-containing medium. (B) Incorporation of 
radiolabeled EPA and DHA into neutral lipids, FFA, and polar lipid fractions in serum-
free and serum-containing medium. (C) FAST-DiI intensity of EL4 cells treated with 
BSA, EPA, or DHA in serum-containing medium. Data are means ± SEM, n = 3. 
Asterisks indicate different from BSA: ***P < 0.001. Data in B were collected by Shaikh, 
S. R. and Harris, M.
In vivo administration of n-3 PUFA did not modify nonraft organization but 
disrupted lipid raft clustering
! Body weights of C57BL/6 mice fed the HF (n-6), LF n-3, and HF n-3 PUFA diets 
did not differ from the CD group after 3 wk (~22 ± 0.3 g). Energy intakes also did not 
differ between these groups and the CD group (11.4 ± 0.1 kcal/d). GC measurements 
confirmed uptake of fatty acids from the diet into B cells (Table 2.2). Cell size did not 
differ between the B cells from the CD group and those from the other groups (data not 
shown).
! Relative to CD, the HF (n-6), LF n-3, and HF n-3 PUFA diets did not increase 
FAST-DiI uptake into B cells (Figure 2.4A). Unexpectedly, the HF n-3 PUFA diet 
decreased plasma membrane and intracellular uptake of C16-Bodipy by ~33% (Figure 
2.4B). The LF n-3 and HF n-6 PUFA diets did not affect C16-Bodipy binding. Sample 
images of FAST-DiI and C16-Bodipy staining are presented in Supplemental Figure 2.3. 
To verify the conclusion that n-3 PUFA did not disrupt nonrafts, MHC I FRET 
experiments were conducted with the HF n-3 PUFA diet, because it lowered C16-Bodipy  
uptake. FRET imaging showed nearly identical FRET efficiency values (~12%) for B 
cells isolated from the CD and HF n-3 PUFA diet-fed mice.
! Finally, we investigated if the HF n-3 PUFA diet disrupted B cell lipid raft 
organization. Microscopy images showed the HF n-3 PUFA diet decreased the 
clustering of lipid rafts (Supplemental Figure 2.4) and increased the Feret diameter of 
the domains by ~40% (Figure 2.4C) compared with CD. In contrast, the HF n-6 and LF 
n-3 PUFA diets, relative to CD, did not affect lipid raft organization.
! In this study, we addressed if n-3 PUFA disrupted nonraft organization of EL4 
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Table 2.2: Fatty acid analysis of B cells isolated from mice fed differing diets
Fatty Acid CD HF (n-6) PUFA LF (n-3) PUFA HF (n-3) PUFA
14:0 0.9 ± 0.2 0.7 ± 0.1 0.6 ± 0.2 0.8 ± 0.1
16:0 24.9 ± 1.7 23.1 ± 2.0 25.8 ± 0.8 24.6 ± 0.5
16:1 0.8 ± 0.2 0.5 ± 0.1 1.0 ± 0.2 1.1 ± 0.1
18:0 16.5 ± 1.2 18.5 ± 2.3 18.5 ± 4.0 19.4 ± 2.8
18:1 trans 0.7 ± 0.2 0.9 ± 0.6 0.9 ± 0.4 0.5 ± 0.2
18:1 cis 14.2 ± 2.4 9.7 ± 0.6 13.2 ± 0.6 12.4 ± 0.6
18:1 (n-7) 1.9 ± 0.5 0.8 ± 0.2 1.7 ± 0.1 1.7 ± 0.1
18:2 (n-6) 17.6 ± 1.6 16.5 ± 1.3 17.1 ± 2.0 18.5 ± 1.0
18:3 (n-6) 0.5 ± 0.3 1.7 ± 0.7 3.6 ± 0.8** 1.6 ± 0.6
18:3 (n-3) 1.6 ± 0.2 1.1 ± 0.1 1.7 ± 0.2 2.3 ± 0.3
20:1 1.1 ± 0.4 1.4 ± 0.4 0.4 ± 0.1 0.7 ± 0.2
20:2 (n-6) 1.4 ± 0.7 1.6 ± 0.7 0.5 ± 0.3 0.7 ± 0.5
20:3 (n-6) 3.5 ± 1.6 0.5 ± 0.2 0.9 ± 0.3 1.0 ± 0.3
20:3 (n-3) 1.1 ± 0.5 1.4 ± 0.2 0.7 ± 0.2 0.8 ± 0.3
20:4 (n-6) 5.1 ± 1.6 3.5 ± 2.0 3.2 ± 0.4 2.4 ± 0.7
20:5 (n-3) 0.2 ± 0.0 0.4 ± 0.1 2.0 ± 0.2* 3.8 ± 0.6***
22:2 (n-6) 1.2 ± 0.4 0.4 ± 0.2 0.1 ± 0.0* 0.4 ± 0.1
22:4 (n-6) 1.2 ± 0.2 1.1 ± 0.4 0.5 ± 0.0* 0.5 ± 0.1*
22:5 (n-6) 0.3 ± 0.1 2.3 ± 1.7 0.3 ± 0.1 0.4 ± 0.1
22:5 (n-3) 1.0 ± 0.4 1.2 ± 0.1 2.7 ± 0.7 2.4 ± 0.4
22:6 (n-3) 1.7 ± 0.4 1.5 ± 0.3 3.0 ± 0.4 3.5 ± 0.6*
24:1 0.9 ± 0.2 0.2 ± 0.1* 0.4 ± 0.0 0.4 ± 0.1
∑SFA 44.6 ± 2.3 46.2 ± 5.2 45.6± 4.5 45.8 ± 2.4
∑MUFA 19.8 ± 3.2 13.6 ± 1.3 17.8 ± 0.6 16.9 ± 0.5
∑PUFA (n-6) 30.6 ± 2.5 26.3 ± 3.9 26.5 ± 3.1 25.6 ± 2.0
∑PUFA (n-3) 5.0 ± 0.7 4.3 ± 0.7 10.1 ± 0.9** 11.7 ± 0.8***
∑PUFA 35.6 ± 3.0 30.7 ± 4.6 36.6 ± 4.0 37.3 ± 2.0
n-6/n-3 6.6 ± 1.0 6.1 ± 0.2 2.6 ± 0.1** 2.2 ± 0.2***
Values (% of total) are mean ± SEM, n=4-5.  Values below 0.5 are not shown for clarity.  
Asterisks indicate different from CD, *P<0.05, **P<0.01, ***P<0.001.
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Figure 2.4: (n-3) PUFA diets did not modify nonraft organization, but the HF (n-3) 
PUFA diet disrupted lipid raft clustering. (A) FAST-DiI intracellular and plasma 
membrane image intensity of B cells isolated from mice fed CD, HF (n-6), LF (n-3), and 
HF (n-3) PUFA diets. (B) C16-Bodipy intracellular and plasma membrane image 
intensity. Fluorescent values in A and B are normalized to CD, because gain settings 
were not the same between differing sets of experiments. (C) Feret diameter of lipid 
rafts. Data are means ± SEM, n = 3–5. Data in C are from 48-143 total cells analyzed 
per diet. Asterisks indicate different from CD: *P < 0.05, **P < 0.01. Data in A-B were 
collected by Franklin, A.
cells followed by translational studies that determined the impact of n-3 PUFA on nonraft 
and lipid raft organization ex vivo. The approach relied on quantitative imaging methods 
to overcome limitations of using detergent extraction (157, 158). As discussed below, 
the data point to an emerging model in which lipid rafts appears more sensitive to 
disruption than nonrafts in response to n-3 PUFA intervention in EL4 and primary B 
cells.
Disruption of nonraft organization in vitro
! In serum free conditions, EPA and DHA treatment modified nonraft organization 
of EL4 cells. There were several possibilities by which EPA or DHA treatment increased 
FAST-DiI in the plasma membrane. One possibility was uptake of FAST-DiI with n-3 
PUFA represented EPA- and/or DHA-rich domains (130, 151). Alternatively, increased 
FAST-DiI accumulation with EPA or DHA represented a dissolving of rafts. Thus, the 
area of nonrafts could have increased upon treatment, but these nonrafts were not 
organizationally distinct domains. To address these 2 possibilities, specific fluorescent 
probes will have to be designed, synthesized, and extensively tested in the future.
! Some other interpretations of the results with FAST-DiI staining were ruled out. 
One possibility was BSA, OA, and AA treatment made FAST-DiI staining of the 
membrane less efficient than EPA or DHA. This was highly unlikely, because we 
observed similar uptake of C16-Bodipy for most of the treatments. A second possibility 
was EPA and DHA decreased the microviscosity of the membrane, which allowed for 
more uptake of the probe (105). Although this was possible, one would then have 
expected increased internalization of the probe with EPA or DHA treatment compared 
with BSA; furthermore, increased uptake of C16-Bodipy would have occurred.
39
! The FRET data with EL4 cells revealed EPA and DHA could modify membrane 
organization on a nanometer scale. To the best of our knowledge, this was the first 
study to use FRET imaging to study nanometer scale organization of n-3 PUFA in a 
cellular system. The data highlight the use of this methodology to determine effects of 
n-3 PUFA on the appropriate size scale. The FRET studies showed EPA and DHA 
increased the distance between randomly distributed nonraft MHC class I molecules.
The increase in cell size with EPA or DHA treatment did not maintain the relative density 
of MHC class I surface molecules compared with the BSA control. We previously 
reported MHC I surface levels on EL4 cells increased by ~30–35% with EPA or DHA 
treatment (150). Here, we found cell size increased by ~26–30% with EPA or DHA. 
Given that forward scatter roughly reports on the diameter of the cell and if we assume 
the cell is a sphere, a ~30% increase in diameter of the cell with EPA and DHA 
treatment should increase surface area by ~60%. Thus, MHC I surface expression 
should have increased >30–35% with EPA or DHA treatment to maintain the same 
density of molecules as the BSA-treated cells. Therefore, as cell size increased, MHC I 
molecules were pushed further apart.
Nonraft organization was not disrupted by n-3 PUFA in vitro or ex vivo when cell 
size was unaffected
! Mechanistically, we speculate an increase in cell size with EPA and DHA 
treatment under serum free conditions caused a redistribution in the lateral organization 
of lipids and proteins. The increase in cell size appeared to be related to the ability of 
EPA and DHA to promote cell growth and prevent cell death. The growth data were 
consistent with previous studies that showed EPA and DHA enhanced cell growth in 
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some cell types (174, 175). Although the numbers of EL4 cells were equivalent across 
the treatment groups at 15.5 h (time point at which studies were conducted), by 24 h, 
there were differences in cell number. Therefore, the data suggest cells treated with 
EPA or DHA at 15.5 h grew in size at a faster rate than the BSA-treated cells and were 
likely poised to divide. It has been reported with primary cells that cell size, measured 
with forward scatter, increased as cells started to divide, because a homogenous 
population of cells can have varying thresholds for entry into the cell cycle (176).
! The ex vivo data also showed n-3 PUFA administered to mice at 2 different 
doses had no effect on nonraft organization. The ex vivo data were consistent with the 
in vitro studies in which EPA and DHA did not affect cell size but inconsistent with the in 
vitro studies in which cell size increased. Several possibilities, which may not be 
mutually exclusive, could explain the discrepancy. First, there was the obvious 
difference in cell size, as discussed above. Second, n-3 PUFA in vitro were 
administered as single fatty acids, whereas the diet provided a complex mixture of 
differing fatty acids. Third, B cells from the mice incorporated much lower levels of n-3 
PUFA compared with EL4 cells. However, in vivo levels were more physiologically 
relevant than those administered in vitro. Indeed, 2 independent imaging experiments 
showed treatment of EL4 cells in serum free conditions with a lower dose (10 µmol/L 
EPA or DHA) did not affect FAST-DiI uptake relative to BSA (data not shown). Overall, 
the in vitro studies using serum free conditions suggest the changes in nonraft 
organization had limited physiological relevance. Of course, our studies do not rule out 
the possibility that nonraft organization could be disrupted with n-3 PUFA in other cell 
types.
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Lipid raft clustering was sensitive to n-3 PUFA
! Unexpectedly, the HF n-3 PUFA diet lowered uptake of C16-Bodipy in B cells. It 
was unlikely the lowered uptake was due to a modification in nonraft organization, 
because we measured no change in FAST-DiI intensity or FRET. One possibility could 
be that as n-3 PUFA increased raft size, it made the membrane more ordered, which 
prevented uptake of C16-Bodipy. Overall, it was unclear why this probe was not 
efficiently recruited into the cell, which we aim to investigate in the future. Nevertheless, 
the HF n-3 PUFA diet disrupted lipid raft organization, which was highly consistent with 
our previous data with EL4 cells in which DHA diminished raft clustering (150). The data 
were also consistent with several studies using in vitro or fat-1 transgenic mouse model 
systems that showed n-3 PUFA disrupted lipid raft molecular organization (128, 140, 
155, 177-179). Specifically, the ex vivo data from this study agreed with an electron 
microscopy study that demonstrated treatment of HeLa cells with DHA had a more 
robust effect on cholesterol-dependent raft domains compared with cholesterol-
independent nonraft domains of the inner plasma membrane leaflet (180).
! The discovery that the HF n-3 PUFA diet made rafts appear larger was the first 
visual evidence of n-3 PUFA dietary intervention having an effect on lipid rafts in an 
animal model. Note that although we interpret the rafts to be larger in size, it is possible 
that they could represent rafts that are much smaller in size but only seem larger due to 
increased levels of GM1. Future studies will have to address whether the disruption in 
raft organization represents the formation of highly ordered raft domains or many small 
raft domains. We also propose lipid raft clustering was diminished, because it was 
reported that cholera toxin binds more efficiently to GM1 raft molecules when they are 
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declustered (181). Surprisingly, the LF n-3 PUFA diet did not exert an effect on raft 
organization. Thus, the levels of n-3 PUFA in this diet may not have been high enough 
to modify lipid rafts. Future studies will have to determine at what dose n-3 PUFA serve 
to disrupt rafts.
Implications
! Although numerous studies have established that n-3 PUFA modify the global 
membrane parameter of microviscosity (105), the specific effects of n-3 PUFA on 
membrane domain organization have generally remained elusive. We show n-3 PUFA 
specifically target the organization of lipid rafts more than nonrafts, which has relevance 
toward understanding how these fatty acids disrupt downstream intracellular signaling 
events or cell-cell communication. The data from this study have implications for several 
model systems. We present 2 examples for simplicity. A recent study demonstrated 
DHA treatment prevented dimerization and recruitment of the Toll-like Receptor 4 into 
lipid rafts (182). Our data suggest DHA could prevent recruitment of the protein into lipid 
rafts from nonrafts as a consequence of the disruption in the spatial distribution of rafts 
(which may be occurring on several length scales). As another example, it was 
proposed that suppression of MDA-MB-231 breast cancer migration with n-3 PUFA was 
due to an inability of the chemokine receptor CXCR4 to cluster, but the mechanism was 
not investigated (183). We propose a disruption in lipid rafts could prevent CXCR4 
clustering and one approach would be to measure CXCR4 clustering with FRET 
imaging on a nanometer scale.
! In summary, data from EL4 and primary B cells suggest lipid rafts are far more 
sensitive to disruption in response to intervention with n-3 PUFA than nonraft domains. 
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Future studies will have to address how n-3 PUFA acyl chains initiate a change in the 
spatial distribution of lipid rafts in the plasma membrane and how this affects protein 
clustering and ultimately cellular function.
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CHAPTER 3: HIGH DOSE OF AN N-3 POLYUNSATURATED FATTY ACID DIET 
LOWERS ACTIVITY OF C57BL/6 MICE2
Introduction
! n-3 PUFAs, the bioactive components of fish and flaxseed oil, are routinely 
consumed by the public as food additives or supplements. They are also recognized to 
have utility for treating metabolic and inflammatory diseases (2, 50, 51, 144, 146). 
Generally, dietary studies evaluating n-3 PUFA efficacy in differing model systems have 
relied on low doses of n-3 PUFAs. With animal studies, investigators have commonly 
used ∼5% (weight/weight) fish or flaxseed oil as intervention, corresponding to 
approximately 2–6% of total energy as n-3 PUFAs (52). This dose, especially of fish oil, 
is often selected to model n-3 PUFA intake of Greenland Eskimos that consume n-3 
PUFAs in the range of 1–6% of total energy (4, 5). A few studies have tested the effects 
of fish or flaxseed oils at higher doses with mixed results on functional endpoints 
(184-186). Overall, very little is known about the effects of high doses of n-3 PUFAs, 
which could have a unique therapeutic niche or could exert negative side effects, raising 
potential safety issues for the general public.
! We previously reported long-term administration of high levels of a mixed fish/
flaxseed oil diet to C57BL/6 mice promoted significant body weight gain (160). These 
findings suggested high doses of n-3 PUFAs increased body weight by lowering activity 
since we ruled out changes in food consumption (160). Therefore, the objective of this 
study was to determine if short-term dietary consumption of a high dose of n-3 PUFAs 
2This research was originally published in Prostaglandins, Leukotrienes, and Essential 
Fatty Acids. Rockett, B. D., M. Harris, & S. R. Shaikh. 2012. High dose of an n-3 
polyunsaturated fatty acid diet lowers activity of C57BL/6 mice. Prostaglandins Leukot. 
Essent. Fatty Acids. 86: 137–140. © Elsevier Ltd.
could lower energy expenditure prior to any large differences in body weight. Studies 
were conducted in comparison to a LF purified mouse CD and a LF n-3 PUFA diet.
Experimental methods
Mice and diets
! All experiments with mice fulfilled guidelines established by the East Carolina 
University Brody School of Medicine for euthanasia and humane treatment. Male 
C57BL/6 mice (∼4–6 weeks old) were placed for 3 weeks on two experimental diets, 
developed in collaboration with Harlan-Laboratories (Madison, WI). Mice were 
administered either a purified CD, 5% fat by weight, a LF n-3 PUFA diet, or a HF n-3 
PUFA diet, 20% fat by weight, as previously described (187). The composition of the 
diets is listed in Table 3.1.
Metabolic cage studies
! Mice were placed in fully automated metabolic cages (TSE Systems) for 4 days 
to monitor activity during week 2. Mice were placed one per cage and were acclimated 
for 48 h followed by data collection for 48 h. Airflow through the cages was held 
constant at 0.5 L/min. 12 h light and dark cycles were maintained with ad libitum access 
to food and water. Locomotor activity in the metabolic cages was measured by the 
breaking of 32 infrared laser beams that span each cage in the xy and yz planes. TSE 
LabMaster software recorded in 20 min intervals each time a series of laser beams 
were broken by ambulatory, rearing, and running wheel activity. Metabolic activity was 
measured via indirect calorimetry recording maximal O2 consumption (VO2) and CO2 
production (VCO2). VO2 and VCO2 values were normalized by the software to body 
weight in kilograms and are reported as ml/h/kg (188). Respiratory exchange ratio 
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Table 3.1: Composition of control, low fat, and high fat n-3 PUFA diets
Formula (g/Kg) CD LF n-3 PUFA HF n-3 PUFA
Casein 185 185 220
L-Cystine 2.5 2.5 3.0
Corn Starch 370 370 174
Mineral Mix, AIN-93M-MX (94049) 35 35 42
Vitamin Mix, AIN-93-VX (94047) 15 15 18
Choline Bitartrate 2.5 2.5 3.0
TBHQ, antioxidant 0.02 0.02 0.06
Maltodextrin 140 140 140
Sucrose 150 150 150
Cellulose 50 50 50
Soybean Oil 50 3.8 15
Flaxseed Oil - 23.1 92.5
Fish Oil - 23.1 92.5
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(RER) was calculated as VCO2/VO2. The data were analyzed for average light and dark 
activity (188). Significance was established using a two-way ANOVA followed by a 
Bonferroni Multiple Comparison t test using GraphPad Prism (188). P values less than 
0.05 were considered significant.
Results
Body weight and food consumption
! Mice weighing 16–19 g were placed on diets. Final body weight gain, confirmed 
with measurements of adipose mass with Echo-MRI, was identical between the CD and 
the experimental diets (data not shown). Mice on the HF n-3 PUFA diet consumed less 
food relative to CD; however, there was no difference in the total kcal consumed 
between the differing diets relative to CD (data not shown).
Metabolic cage studies
! The time course of ambulatory, rearing, and running wheel activities are shown in 
Figure 3.1A–C. These data were used to calculate the average activity for the entire 
light and dark cycles (Figure 3.1D–F). There was a significant increase in activity during 
the dark cycle with all of the diets relative to the light cycle for all measurements (Figure 
3.1D–F).
! There were no statistical differences between the diets during the light cycle. The 
HF n-3 PUFA diet lowered average dark cycle ambulatory activity by 62% relative to CD 
(Figure 3.1D). The LF n-3 PUFA diet had no significant effect compared to CD. Rearing 
activity was significantly lowered with the HF n-3 PUFA diet by 63% compared to CD 
(Figure 3.1E). The LF n-3 PUFA diets had no effect on rearing activity relative to CD. 
For the ambulatory and rearing measurements of activity, there were no significant 
48
49
Figure 3.1: HF n-3 PUFA diet lowered activity. (A) Ambulatory, (B) rearing, and (C) 
running wheel activities as a function of time for mice fed differing diets. Corresponding 
average light and dark cycle (D) ambulatory, (E) rearing and (F) running wheel activities. 
Counts represent the number of laser beams broken due to movement in the cage. 
Data are mean ± SEM, n = 7 mice per diet. Significance during the dark cycle compared 
to CD is indicated by *P < 0.05, †P < 0.01, ‡P < 0.001.
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differences in activity between the LF n-3 PUFA and HF n-3 PUFA diets. Running wheel 
activity was lowered with the HF n-3 PUFA diet relative to CD by 87%, and 78% relative 
to the LF n-3 PUFA (Figure 3.1F). The LF n-3 PUFA diet had no effect on running wheel 
activity relative to CD.
! The time course of VO2, VCO2, and RER values is shown in Figure 3.2A–C. 
These data were then used to calculate the average VO2, VCO2, and RER for the entire 
light and dark cycles (Figure 3.2D–F). The average dark cycle VO2 (Figure 3.2D) and 
VCO2 (Figure 3.2E) were significantly higher for all of the diets relative to the light cycle. 
There were no differences between the diets on VO2. The HF n-3 PUFA diet lowered 
dark cycle VCO2 by 20% relative to CD and LF n-3 PUFA. RER values were significantly 
different for all of the diets between the light and dark cycles (Figure 3.2F). During the 
dark cycle, the HF n-3 PUFA had lower RER values relative to CD and LF n-3 PUFA.
Discussion
! We present evidence for the first time that a high dose of n-3 PUFAs lowered 
mouse activity. The reduction in activity with the HF n-3 PUFA diet was consistent with 
our previous study demonstrating this diet promoted significant body weight gain in mice 
(160). The LF n-3 PUFA diet also had a tendency to reduce energy expenditure in some 
of the measurements. This raises the question of whether mixing fish and flaxseed oils 
has some potential effect that does not promote body weight loss and perhaps even 
increase body weight gain after long-term feeding due to a reduction in activity. More 
studies are needed to address this in addition to determining the effects of other fat 
sources (i.e. hydrogenated oils, coconut oil) on activity. Overall, the reduction in all three 
measures of activity (ambulatory, rearing, and running wheel) appeared dose 
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Figure 3.2: HF n-3 PUFA diet lowered VCO2 and RER. (A) VO2, (B) VCO2, and (C) 
RER as a function of time for mice fed differing diets for 3 weeks. Corresponding 
average light and dark cycle (D) VO2, (E) VCO2, and (F) RER. VO2 and VCO2 are mL of 
gas consumed or expelled per hour normalized to body weight. Data are mean ± SEM, 
n = 7 mice per diet. Significance during the dark cycle compared to CD is indicated by 
*P < 0.05, ‡P < 0.001.
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Figure 3.2
dependent with the n-3 PUFA diets.
! It is difficult to directly compare our data to other studies since there are very few 
studies in this area, which are not in complete agreement. For instance, an EPA 
enriched oral food supplement provided to advanced pancreatic cancer patients, who 
are prone to losing weight, enhanced energy expenditure, and provided some 
improvement in their metabolism (189). However, in another set of studies, 
supplementing the diet of healthy males with fish or flaxseed oil had no effect on energy 
expenditure (190, 191). Clearly, more studies are needed in this area with n-3 PUFAs in 
both animals and humans.
! Overall, the potential therapeutic value of high n-3 PUFA doses appears very 
limited. It is interesting that despite lowering activity, the HF n-3 PUFA diet reduced 
serum triglycerides (data not shown). Therefore, the data suggest high doses of n-3 
PUFAs are effective in their accepted role of lowering triglycerides (TG) even when they 
lower activity. There are a few cases where an increase in body fat mass due to lower 
activity could have some value. For instance, HIV positive patients can have elevated 
TGs and high energy expenditure, yet low body weight, which are in part driven by 
aggressive anti-viral therapy (192, 193). The elevated TGs are a risk factor for 
cardiovascular disease, which is prevalent in HIV positive patients (194). Perhaps short-
term intervention with a high dose of fish/flaxseed oils would assist in lowering TGs and 
lowering energy expenditure. Of course, extensive functional and mechanistic studies in 
animals and eventually humans would be required to address at what specific dose, 
composition of n-3 PUFAs, and duration could these fatty acids be utilized for these 
cohorts.
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CHAPTER 4: FISH OIL INCREASES RAFT SIZE AND MEMBRANE ORDER OF B 
CELLS ACCOMPANIED BY DIFFERENTIAL EFFECTS ON FUNCTION3
Introduction
! Fish oil (FO) enriched in n-3 PUFAs is increasingly hypothesized to have 
beneficial health effects for treating symptoms for a wide range of diseases associated 
with chronic inflammation (17, 195, 196). However, several hurdles have prevented the 
therapeutic use of FO in the clinic, including a limited understanding of the molecular 
targets and mechanisms of n-3 PUFAs. The proposed mechanisms by which the n-3 
PUFAs of FO, EPA and DHA, exert immunosuppressive effects are pleiotropic (197). 
These include incorporating into membrane phospholipids and modifying plasma 
membrane microdomain organization, serving as precursors for bioactive lipid 
molecules, disrupting intracellular signaling, and regulating gene expression (197). 
Recently, manipulation of lipid raft microdomains with n-3 PUFAs has gained attention 
because this mode of action is central to many of the downstream effects of n-3 PUFAs 
(149).
! Several models, which are not in complete agreement, have emerged to explain 
how n-3 PUFAs disrupt raft molecular organization. One model, based on ex vivo 
studies of the CD4+ T-cell immunological synapse, is that n-3 PUFAs, relative to 
controls, enhance the formation of more ordered and possibly larger lipid rafts upon 
stimulation of the cell (140). This model is the most relevant because it relied on the 
3This research was originally published in The Journal of Lipid Research. Rockett, B. D., 
H. Teague, M. Harris, M. Melton, J. Williams, S. R. Wassall, & S. R. Shaikh. Fish oil 
increases raft size and membrane order of B cells accompanied by differential effects 
on function. J Lipid Res. 2012; 53; 674–685. © the American Society for Biochemistry 
and Molecular Biology.
fat-1 transgenic mouse that has higher endogenous levels of n-3 PUFAs compared with 
control mice. A second model developed with studies in model membranes is that 
phosphatidylethanolamines containing DHA largely avoid raft molecules to form their 
own entities as nonraft domains (198, 199). Finally, a more integrated model, based 
mostly on in vitro studies, is that n-3 PUFAs incorporate directly into rafts and in some 
cell types force cholesterol molecules to undergo displacement between rafts and 
nonrafts (149, 200, 201). Overall, the majority of these models have not relied on 
physiologically relevant conditions that model human intake of FO.
! Based on studies with CD4+ T cells, macrophages, and splenocytes, disruption of 
rafts with n-3 PUFAs generally suppresses cellular function (140, 142, 143). Far less is 
known about the relationship between disruption of lipid rafts with n-3 PUFAs and 
downstream function in other cell types. In particular, B cells are increasingly recognized 
to have a role in inflammatory processes and autoimmune diseases (202, 203); 
however, there is limited understanding about how FO affects B cell membrane 
organization and function, especially at the animal level. We previously demonstrated 
that feeding C57BL/6 mice a very high dose of n-3 PUFAs for 3 weeks diminished B cell 
lipid raft clustering (187). We also showed that mice consuming this very high dose for 
14 weeks displayed enhanced B cell activation, which we speculated was due to an 
increase in body weight (160). However, we did not completely test the effects of a 
physiologically relevant dose of FO on raft organization, the mode of raft disruption, or 
its relationship with innate and adaptive B cell function.
! The specific objectives of this study were 1) to determine if administration of a 
dose of FO, modeling human intake, disrupted lipid raft organization of mouse B cells; 
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2) to address the conflicting models on how n-3 PUFAs disrupted raft molecular 
organization; and 3) to test the hypothesis that altering raft organization with FO would 
promote immunosuppressive effects on downstream innate and adaptive B cell function. 
The approach relied on biochemical and imaging measurements of B cells isolated from 
mice fed FO, supplemented with in vitro and model membrane studies. The data 
revealed for the first time that a relevant dose of FO increased B cell raft size and 
membrane molecular order upon cross-linking rafts, which was accompanied by novel 
downstream functional effects.
Materials and Methods
Mice and diets
! Male C57BL/6 mice (Charles River), 4–6 weeks old, were fed for 3 weeks a 
purified CD or a FO diet (Harlan-Teklad). Both diets consisted of 5% total fat by weight 
or 13% by total energy. All ingredients were essentially identical except the fat source, 
which was soybean oil in the CD and menhaden fish oil in the FO diet (Table 4.1). The 
FO diet also contained food coloring, which we ensured had no effects on the 
measurements described below. The fatty acid distribution of the diet, measured with 
GC, was within experimental error to that reported by the vendor (Harlan-Teklad) 
(Supplementary Table 4.1). Approximately 2% of the total kcal came from EPA and 1.3% 
from DHA. This level of EPA/DHA corresponded to approximately 4 g of FO consumed 
by a human on a daily basis, which can be achieved through the diet and is currently in 
use pharmacologically for treating elevated triglycerides (52). Mice were euthanized 
using CO2 inhalation and cervical dislocation followed by isolation of spleens. All of the 
experiments with mice fulfilled the guidelines established by the East Carolina 
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Table 4.1: Composition of control and fish oil diets.
Formula (g/Kg) Control Fish oil
Casein 185.0 185.0
L-Cystine 2.5 2.5
Corn Starch 369.98 369.88
Maltodextrin 140.0 140.0
Sucrose 150.0 150.0
Cellulose 50.0 50.0
Soybean Oil 50.0 -
Fish Oil - 50.0
Mineral Mix, AIN-93M-MX (94049) 35.0 35.0
Vitamin Mix, AIN-93-VX (94047) 15.0 15.0
Choline Bitartrate 2.5 2.5
TBHQ, antioxidant 0.02 0.02
Yellow food coloring - 0.1
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University Brody School of Medicine for euthanasia and humane treatment.
Cell isolation and cell culture
! B220+ B cells (> 90% purity) were isolated from splenocytes by negative 
selection (Miltenyi Biotech) as previously described (160). For some experiments, CD4+ 
T cells (> 85% purity) were purified from B6.Cg-Tg(TcraTcrb)425Cbn/J mice (OT-II) 
(Jackson Laboratory) that express α- and β-chain T-cell receptor and CD4 co-receptor 
specific for recognizing chicken ovalbumin 323–339 (OVA323–339) presented by H-2 IAb 
molecules. For in vitro studies, mouse EL4 lymphomas were treated with 25 µM EPA or 
DHA complexed to BSA for 15.5 h as previously described (150). BSA without 
complexed fatty acid served as the control (150).
Isolation of detergent-resistant membranes and analysis
! A total of 30 × 106 B cells or 20 × 106 EL4 cells were prepared for detergent 
extraction and layered on a sucrose gradient as previously described (150). Sucrose 
gradients were centrifuged at 40,000 rpm for 20 h at 4°C in a swinging bucket SW41Ti 
rotor (Beckman). Twelve 1 ml fractions were collected. Fractions 3–6 representing 
detergent-resistant membranes (DRMs) or fractions 9–12 representing detergent-
soluble membranes (DSMs) were combined based on their cholesterol content, which 
was measured with an Amplex Red cholesterol assay kit (Invitrogen) relative to protein 
levels. Lipids were extracted as described previously (150). Samples were dissolved in 
chloroform, and select phospholipids were separated with a Shimadzu Prominence 
HPLC using a 150 × 4.6 mm Luna 5 µm NH2 column (Phenomenex) with a mobile 
phase gradient of H2O (increasing from 5% to 50%) and acetonitrile (decreasing from 
95% to 50%) at 30°C. Phosphatidylethanolamine (PE), phosphatidylcholine (PC), and 
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sphingomyelin (SM) fractions were collected by UV detection at 202 nm, and the acyl 
chain composition of each fraction was further analyzed by GC as previously shown 
(150). The rationale for selecting these phospholipids was to address the most 
abundant lipids of the outer (PC, SM) and inner (PE) leaflets and to allow direct 
comparison with other studies (128).
2H NMR spectroscopy
! Sample preparation, NMR spectroscopy, and analysis were as previously 
described (198). The PC phospholipid (1-[2H31] palmitoyl-2-
docosahexaenoylphosphatidylcholine,16:0-22:2PC-d31) used for this study was 
perdeuterated in the sn-1 chain (custom synthesis, Avanti Polar Lipids), and the 
samples consisted of aqueous multilamellar dispersions of 50 wt% lipid in 50 mM Tris 
buffer (pH 7.5). Briefly, lipid mixtures of 16:0-22:6PC-d31/SM (1:1) and 16:0-22:6PC-d31/
SM/cholesterol (1:1:1) were codissolved in chloroform. The solvent was removed, the 
lipids were hydrated with buffer, and the pH was adjusted. After three lyophilizations 
with deuterium-depleted water (Sigma), samples were transferred to a 5 mm NMR tube. 
Stringent precautions were taken to prevent oxidation during sample preparation and 
data acquisition. NMR experiments were performed on a homebuilt spectrometer 
operating at 7.05 T using a phase-alternated quadrupolar echo sequence (199, 204).
Lipid raft cross-linking and total internal reflection fluorescence imaging
! Cells were fluorescently stained for lipid rafts by cross-linking CTx-B (Invitrogen) 
and then imaged using total internal reflection fluorescence (TIRF) microscopy. For 
select experiments, GM1 levels were measured by staining with primary with no 
secondary antibody for cross-linking. TIRF was performed on an Olympus IX-71 
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microscope with excitation at 488 nm by a 20 mW Sapphire laser and a 60× 1.45NA oil-
immersion TIRF objective. Fluorescence emission was filtered through a LF-488/561-A-
OMF filter cube (Semrock) and detected by a Hamamatsu ORCA-R2 progressive scan 
interline CCD camera. For all imaging experiments, 9 or 10 cells per diet were analyzed 
per experiment, and image analysis was performed as previously described (150).
Live cell imaging of DiIC18
! To assess changes in nonraft organization, we measured uptake of the nonraft 
probe 1,1’-dioctadecyl-3,3,3′,3′-tetramthylindocarbocyanine perchlorate (DiIC18, 
Invitrogen) (205). The approach was similar to our previous report where we used 
FAST-DiI (187). However, FAST-DiI uptake was extremely rapid under live cell imaging 
conditions; therefore, we relied on DiIC18. A total of 1 × 106 B cells were washed with 
RPMI 1640 without phenol red at 37°C and resuspended in 1 ml of the same media and 
placed into Delta T dishes (Bioptechs Inc.). We added 0.2 µl of a 1 mg/ml stock of 
DiIC18 to the dishes and imaged. Live cell, wide-field microscopy was conducted with an 
Olympus IX-70 microscope using an oil 100× objective and a Hamamatsu CCD camera, 
equipped with stage and objective heaters (Bioptechs Inc.). Imaging was started at 1 
min after addition of the fluorescent probe at 37°C. Images were acquired with 
MetaMorph software and analyzed with NIH ImageJ. All settings were kept constant 
between experiments.
Generalized polarization imaging
! Generalized polarization (GP) was calculated to determine the molecular order of 
the B and EL4 cell plasma membrane (206). Cells were stained with 4 µM di-4-
ANEPPDHQ (Invitrogen) for 30 min at 37°C, washed twice with PBS, and fixed with 4% 
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paraformaldehyde (207). For some experiments, as an additional control, B cells were 
treated with 10 µM methyl-β-cyclodextrin (Sigma-Aldrich) for 15 min at 37°C to deplete 
cholesterol. Imaging was conducted on a Zeiss LSM-510 confocal microscope using a 
100x objective with excitation at 488 nm and fluorescence emission detected in two 
channels: 505–545 nm for ordered regions and 650–750 nm for disordered regions. 
Quantification of fluorescence intensity (I), after background subtraction for the two 
channels, was performed using NIH ImageJ. GP was calculated using the formula: GP 
= (I505–545 − (G)I650–750)/(I505–545 + (G)I650–750), where G is the G-factor and I is 
fluorescence intensity (206).
B cell activation with lipopolysaccharide (LPS)
! B cells were stimulated with 1 µg/ml of LPS for 24 h, and the secreted cytokine 
profiles were measured from supernatants using a Multi-Analyte ELISArray kit (SA 
Biosciences) as previously demonstrated (160). In addition, B cells were analyzed for 
surface expression of activation markers using fluorescently labeled anti-MHC class II 
M5/114.15 (Bio X Cell), anti-CD69 H1.2F3 (BD Biosciences), and anti-CD80 16-10A1 
(Bio X Cell) on a BD LSR II flow cytometer. Antibodies for MHC class II and CD80 were 
conjugated with fluorophores using a kit (GE Healthcare).
B cell activation of naive CD4+ T cells
! B cells were peptide loaded with OVA323–339 (GenScript) at various concentrations 
in serum-free media for 1 h at 37°C and then washed with fresh media. A total of 1 × 105 
B cells were then plated with 3 × 105 nondiet modified OT-II transgenic T cells, spun 
quickly, and incubated for 24 h at 37°C in 96-well plates. After 24 h, the supernatant was 
collected to analyze secreted IFN (interferon)-γ and IL-2 with an ELISArray kit (SA 
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Biosciences) following the manufacturer's protocol. The cells were stained with 
fluorescently labeled anti-CD4-PE (Miltenyi Biotech), anti-CD69-FITC (BD Biosciences), 
and anti-CD25-PE-Cy7 (BD Biosciences) and analyzed by flow cytometry on a BD LSR 
II. In all flow cytometry experiments, SYTOX Blue (Invitrogen) was used to discriminate 
dead cells, and at least 10,000 live events were collected for analyses. Control 
experiments were routinely conducted in the absence of peptide and with T cells only 
(no B cells) to ensure T-cell activation was driven by peptide-loaded B cells.
Statistical analyses
! All ex vivo and in vitro data are from several independent experiments, with each 
ex vivo experiment representing one mouse per diet. The only exception was the ex 
vivo DRM/DSM analysis, in which two mice were pooled per experiment. Data were first 
analyzed for normality using a Kolmogorov-Smirnov test (GraphPad Prism). For a few 
select experiments with nonparametric distributions, we relied on paired Wilcoxon t-
tests. Pairing was required due to differences in experimental settings between 
experiments as previously described (187). For the majority of animal experiments, 
statistical significance was established using an unpaired one-tailed or two-tailed 
Student's t-test. One-tailed unpaired t-tests were used to analyze the GC data from 
animals because before experimentation we predicted an increase in n-3 PUFA levels 
(128). In vitro studies relied on one-way ANOVAs followed by a Dunnett's post hoc t-test 
(160). P values less than 0.05 were considered significant. The NMR data were not 
analyzed for statistical significance because they were obtained on model membranes 
of well defined and controlled composition for which a reproducibility of ±1% applies to 
multiple acquisitions. This approach is standard for model membrane studies using 
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NMR spectroscopy (198, 199).
Results
Body weights, food intake, and cellularity
! The FO diet, relative to CD, had no effect on the rate of body weight gain 
(Supplementary Figure 4.1A) or food intake per day (Supplementary Figure 4.1B). 
Spleen weight (Supplementary Figure 4.1C) was significantly elevated for mice on the 
FO diet but did not affect the steady-state number of B cells (data not shown). Given 
that we recently reported n-3 PUFAs at high doses can lower energy expenditure (208), 
we verified that the FO diet had no impact on whole body energy expenditure using 
metabolic cages (data not shown).
FO promoted uptake of EPA/DHA into DSMs and DHA into PC of DRMs
! The first objective was to biochemically determine if the physiologically relevant 
dose of FO manipulated the molecular composition of B cell “raft”-like DRMs. We used 
detergent extraction followed by HPLC-GC to determine the acyl chain composition of 
PE, PC, and SM ex vivo (Figure 4.1). The relative proportion of PC, PE, and SM in DRM 
and DSM fractions was not changed by FO (Figure 4.1A). Relative PC and SM levels 
were generally higher in DRMs than in DSMs. SM was the smallest fraction of PE/PC/
SM, consistent with studies in other cell types (177).
! In PE, EPA (20:5) and DHA (22:6) did not incorporate into DRMs but were 
significantly increased in DSMs (Figure 4.1B). FO also increased 22:5 and lowered 
arachidonic acid (20:4) in PE DSMs (Figure 4.1B). In PC, 20:5 was lowered and 22:6 
increased with FO in DRMs (P = 0.06) (Figure 4.1C). In DSMs of PC, 20:5 and 22:6 did 
not significantly increase (Figure 4.1C). In SM, 20:5 and 22:6 did not change in DRMs 
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Figure 4.1: FO promoted uptake of EPA/DHA into DSMs and DHA into PC of 
DRMs. (A) Relative levels of B-cell PE, PC, and SM of DRM (left) and DSM (right) 
fractions. Acyl chain composition of B-cell DRM or DSM fractions of (B) PE, (C) PC, and 
(D) SM. B cells were isolated from mice fed control or FO-enriched diets. Data are 
means ± SEM (n = 4, with two mice pooled per experiment). Asterisks indicate different 
from control: *P < 0.05; **P < 0.01; ***P < 0.001.
(Figure 4.1D). In DSMs of SM, FO significantly decreased palmitic acid (16:0) and 
increased stearic acid (18:0), 20:5, 22:5, and 22:6 (Figure 4.1D). Because we did not 
quantify the exact levels of EPA and DHA, we conducted a few select experiments to 
approximate the levels EPA and DHA incorporating into DRMs and DSMs (data not 
shown). On average, ∼5–8% of the total n-3 PUFA were localized to DRMs with the 
remaining amount in DSMs, consistent with another study (209).
! Cholesterol levels in DRM and DSM fractions were not changed with FO 
(Supplementary Table 4.2). We also analyzed the ratio of DRM to DSM cholesterol 
based on a very recent study that reported that DHA treatment in vitro increased 
cholesterol into DSMs when analyzed as a ratio (200). FO had no effect on the ratio 
(Supplementary Table 4.2).
! Overall, the data were highly consistent with predictions from detergent-free 
model membrane studies in which PCs containing DHA were found to have higher 
solubility for cholesterol, and by implication to have more favorable interactions with 
rafts, than PEs containing DHA (152). We confirmed this by comparing the order of 
cholesterol on the perdeuterated sn-1 chain on a DHA-containing PC (16:0-22:6PC-d31) 
vs. a DHA-containing PE (16:0-22:2PE-d31) in mixtures with SM (1:1) and SM/
cholesterol (1:1:1), mimicking rafts, using 2H NMR spectroscopy (Table 4.2) (198). The 
increase in order due to cholesterol (reflecting proximity), measured for the PC-
containing DHA, was more than twice that for the PE-containing DHA (Table 4.2). This 
observation was consistent with the ex vivo biochemical data that suggest DHA 
infiltrated into PCs of DRMs and PEs of DSMs.
FO increased B cell lipid raft size induced by cross-linking GM1
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Table 4.2: DHA-containing PC displayed increased molecular order in the 
presence of lipid raft molecules relative to PE. Average order parameter values were 
calculated from 2H NMR spectra collected at 40°C for mixtures of 16:0-22:6PC-d31 with 
sphingomyelin (1:1), and with sphingomyelin and cholesterol (1:1:1).  Values for 
16:0-22:6PE-d31 were from previously published data (198). Data were collected by 
Williams, J. and Wassall, S. R.
Lipid mixture Order parameter value
Percent increase 
in order
16:0-22:6PC-d31/Sphingomyelin 0.115
68.7%
16:0-22:6PC-d31/Sphingomyelin/Cholesterol 0.194
16:0-22:6PE-d31/Sphingomyelin 0.150
26.0%
16:0-22:6PE-d31/Sphingomyelin/Cholesterol 0.189
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! The next objective was to measure changes in raft organization with the FO diet 
relative to the CD using microscopy. This was essential because biochemical 
approaches are a useful predictive tool but also have limitations due to the use of 
detergent (158, 159). TIRF imaging of B cells from FO- and CD-fed mice showed a 
significant difference in the spatial distribution of GM1 molecules cross-linked with CTx-
B (Figure 4.2A). TIRF image analysis, confirmed with confocal image analysis (data not 
shown), revealed the Feret's diameter was increased by 79% with FO relative to CD 
(Figure 4.2B). The binding of CTx-B to GM1 in the presence of cross-linking, measured 
in terms of fluorescence intensity, showed on average a 36% increase with FO, but this 
failed to reach statistical significance with TIRF analysis (Figure 4.2C). To determine if 
the propensity for an increase in CTx-B intensity was due to increased surface levels of 
GM1, the binding of CTx-B in the absence of cross-linking was measured, which 
revealed a 49% increase in intensity with FO (Figure 4.2D). To ensure the observed 
effects were FO specific, we also measured raft size and binding of CTx-B with a 
safflower oil-enriched diet and found no evidence of raft disruption with this diet 
(Supplementary Figure 4.2). We also ensured the effects were specific for rafts. 
Changes in nonraft organization were measured in terms of uptake of the nonraft probe 
DiIC18 (205). Live cell imaging revealed that DiIC18 uptake was identical between cells 
isolated from CD- and FO-fed mice (Supplementary Figure 4.3). The imaging results 
provided the first evidence that a physiologically relevant dose of FO disrupted raft, but 
not nonraft, organization.
FO increased membrane order upon cross-linking rafts relative to the absence of 
cross-linking
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Figure 4.2: FO increased the size of rafts induced by CTxB cross-linking. (A) 
Sample fluorescence images of B cells isolated from control or FO-fed mice and cross-
linked to induce raft clustering. Images are from TIRF microscopy (bar, 5 µm). (B) Lipid 
raft size in terms of Feret’s diameter for B cells. (C) CTxB fluorescence intensity after 
cross-linking. (D) GM1 surface levels. Values are means ± SEM (n = 6 from 65 total 
cells analyzed per diet in A–C; n = 4 from 86-90 cells analyzed per diet in D). Asterisks 
indicate different from control: ***P < 0.001.
! We subsequently determined if the aforementioned changes with FO on raft 
organization affected membrane molecular order. This directly addressed two opposing 
models in which n-3 PUFAs in response to stimulation increase membrane order ex vivo 
versus a decrease in membrane order in vitro (140, 177). To measure molecular order, 
we used di-4-ANEPPDHQ, an environmental sensing fluorescent dye that can shift its 
emission spectra 30 nm depending on the degree of packing in the surrounding lipid 
chains (Figure 4.3A) (210). As an initial control, B cells were treated with 10 µM methyl-
β-cyclodextrin to remove cholesterol from the membrane. GP significantly decreased 
upon cholesterol depletion (data not shown). In the absence of cross-linking, FO, 
compared with CD, significantly decreased the average GP by 25% (Figure 4.3B). This 
decrease was consistent with data showing that n-3 PUFAs exert a disordering effect on 
membrane microviscosity in the absence of inducing raft formation (105). Although there 
was no difference in GP values between CD and FO diets upon cross-linking (Figure 
4.3C), GP values for FO were elevated to a greater extent than CD relative to no cross-
linking (Figure 4.3D). Analysis of the differences in GP values between cross-linking and 
no cross-linking showed FO had a greater ordering effect by 65% compared with CD 
(Figure 4.3D). These results supported the ex vivo model that FO is capable of exerting 
an ordering effect on the membrane upon stimulation (140).
EPA and DHA incorporated into DRMs/DSMs and did not increase GM1 surface 
expression in vitro
! We previously reported that treatment of EL4 cells with DHA, but not EPA, 
increased raft size (150). Therefore, we conducted comparative biochemical and 
imaging studies to determine if the in vivo and in vitro modes of raft disruption were 
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Figure 4.3: FO increased B-cell membrane molecular upon cross-linking relative 
to no cross-linking. (A) Sample merged intensity images of B cells, stained with di-4-
ANEPPDHQ, isolated from control or fish oil enriched diets. Ordered (green) and 
disordered (red) channels are merged to illustrate the ratio between channels. B: 
Plasma membrane GP values from B cells isolated from control and FO-fed mice 
without CTxB cross-linking. C: GP analysis of B cells cross-linked with CTxB. D: 
Change in GP values upon cross-linking CTxB relative to no cross-linking. Values are 
means ± SEM (n = 4 from 40 total cells analyzed per diet). Asterisks indicate different 
from control: *P < 0.05; **P < 0.01.
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similar in addition to discriminating differences in bioactivity of EPA vs. DHA.
! Similar to ex vivo measurements, relative PC and SM levels were higher in 
DRMs than in DSMs and were not affected by EPA or DHA (Figure 4.4A). In PE, EPA 
treatment increased 20:5 and 22:5 in DRMs. DHA treatment had no significant effect on 
22:6 in DRMs of PE (Figure 4.4B). In PE DSMs, EPA and DHA treatment lowered 20:4 
and DHA increased 22:6 (Figure 4.4B). In PCs, EPA and DHA treatment did not 
significantly increase 20:5 or 22:6 in DRMs (Figure 4.4C). In PC DSMs, EPA and DHA 
treatment, respectively, increased 20:5/22:5 and 22:6 levels. EPA and DHA treatment 
lowered 18:1 in DRMs and DSMs of PC. In SM, EPA and DHA, respectively, increased 
20:5 and 22:6 in DRMs (Figure 4.4D). In DSMs of SM, EPA and DHA lowered 18:1 and, 
respectively, increased 20:5/22:5 and 22:6. Similar to the ex vivo studies, we did not 
quantify exact levels of EPA and DHA in DRM/DSM. Based on a few select studies 
(data not shown), ∼30% of the added EPA/DHA was localized to DRMs with the 
remaining amount in DSMs, consistent with our previous work (150).
! Cholesterol levels in the DRM and DSM fractions were not significantly changed 
with EPA or DHA treatment (Supplementary Table 4.2). There was a tendency for EPA 
treatment to lower DRM cholesterol relative to BSA when analyzed as a t-test (P < 
0.05). The ratio of cholesterol in DRM to DSM also had a tendency to be lowered with 
EPA and DHA treatment (P = 0.08) (Supplementary Table 4.2). Finally, we measured 
GM1 surface levels using microscopy before and after cross-linking and found no effect 
of EPA or DHA treatment (Supplementary Figure 4.4). These results showed that in vitro 
treatment with EPA/DHA, consistent with most other in vitro studies, changed DRM 
composition (128, 154); however, we did not measure an increase in GM1 levels in vitro 
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Figure 4.4
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Figure 4.4: EPA and DHA treatment targeted DRM and DSM composition of EL4 
cells. (A) Relative levels of PE, PC, and SM of EL4 DRM (left) and DSM (right) 
fractions. Acyl chain composition of DRM or DSM fractions from (B) PE, (C) PC, and (D) 
SM. EL4 cells were treated with BSA, 25 µM EPA, or DHA. Values are means ± SEM (n 
= 4). Asterisks indicate different from control: *P < 0.05; **P < 0.01; ***P < 0.001.
with EPA or DHA treatment as observed ex vivo.
DHA, but not EPA, increased membrane order with cross-linking relative to the 
absence of cross-linking in vitro
! We next determined if EPA and DHA treatment increased membrane order as 
measured ex vivo. In the absence of cross-linking, EPA and DHA, respectively, 
compared with BSA, decreased GP by 32% and 75% (Figure 4.5A). Upon cross-linking, 
EPA showed no difference in molecular order relative to BSA; however, DHA treatment 
lowered GP by 27% (Figure 4.5B). Analysis of the differences in GP values between 
cross-linking relative to no cross-linking showed DHA, but not EPA, had a greater 
ordering effect by 60% compared with BSA (Figure 4.5C). These results supported the 
emerging ex vivo model that an n-3 PUFA exerts an ordering effect upon induction of 
raft formation (140).
FO enhanced B cell activation in response to LPS stimulation but suppressed B 
cell stimulation of naive CD4+ T cells
! The next set of experiments tested the hypothesis that disruption of lipid raft 
organization with FO would be accompanied by suppressive effects on downstream 
innate and adaptive B cell function, as reported for T cells, macrophages, and 
splenocytes (140, 142, 143). Two different B cell functional studies were conducted. 
First, we measured the activation of B cells after 24 h of LPS stimulation as a measure 
of an innate response (Figure 4.6). We found the physiologically relevant dose of FO 
enhanced B cell activation. The number of B cells activated was the same between the 
CD and FO diets (data not shown). CD69 surface levels were increased by 22% with 
FO, whereas MHC class II and CD80 surface expression were not affected by FO 
74
75
BSA EPA DHA
0.0
0.1
0.2
0.3
0.4
G
P
Treatment
**
***
Treatment
G
P
BSA EPA DHA
0.0
0.1
0.2
0.3
0.4
0.5
***
Treatment
 Δ
 M
ol
ec
ul
ar
 o
rd
er
BSA EPA DHA
0.0
0.1
0.2
0.3 **
No cross-linking
A.
Cross-linked
B.
C.
Figure 4.5
76
Figure 4.5: DHA, but not EPA, increased membrane molecular order upon cross-
linking relative to no cross-linking in vitro. (A) Plasma membrane GP values from 
EL4 cells treated with BSA, EPA, or DHA without CTxB cross-linking. (B) GP analysis of 
EL4 cells cross- linked with CTxB. (C) Change in GP values upon cross-linking CTxB 
relative to no cross-linking. Values are means ± SEM (n = 3 from 36 cells analyzed per 
treatment). Asterisks indicate different from control: **P < 0.01; ***P < 0.001.
(Figure 4.6A). Secretion of IL-6, TNF-α, and IFN-γ were increased compared with FO 
relative to the CD by 43, 87, and 182% (Figure 4.6B). IL-10 secretion was unaffected 
with the FO diet (Figure 4.6B).
! To determined if the immune enhancing effect of the FO diet on B cells was 
specific to the innate response or applicable to an adaptive immune response, we 
tested the ability of B cells isolated from FO-fed mice to stimulate transgenic naive CD4+ 
T cells that were not from FO-fed mice (Figure 4.7). The concentration of OVA323–339 
peptide loaded into B cells was optimized for maximal activation at 10−5 M with no 
activation at 0 M (data not shown). FO had no impact on the percentage of 
CD4+CD69+CD25+ T cells activated (data not shown). In addition, the surface 
expression of the activation markers CD69 and CD25 on CD4+ T cells was unchanged 
with FO (Figure 4.7A). Analysis of secreted cytokines revealed that IFN-γ levels were 
not significantly decreased with FO, but IL-2 secretion was decreased by 42% with the 
FO diet relative to CD (Figure 4.7B). These results supported the notion that raft 
disruption with FO was accompanied by changes in B cell function.
Discussion
! In this study, we focused on B cells, a cell type underrepresented in experiments 
with n-3 PUFAs, especially at the animal level. The results demonstrated several 
significant advancements. First, the data showed that a relevant dose of FO increased 
the size of B cell rafts. Next, data integrated from animals, cell culture, and model 
membranes challenged some models on how n-3 PUFAs disrupted raft molecular 
organization. Third, the data highlighted differences between EPA and DHA on 
membrane organization. Finally, we discovered that a physiologically relevant dose of 
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Figure 4.6: FO increased B-cell CD69 expression and cytokine secretion upon 
activation with LPS. (A) Median fluorescence intensity for B cells stained with anti-
MHC class II, anti-CD80, or anti-CD69 after 24 h of LPS activation. B cells were isolated 
from mice fed a control or FO diet. (B) Cytokine secretion after 24 h of LPS activation. 
Values are means ± SEM (n = 6). Asterisks indicate different from control: *P < 0.05; 
**P < 0.01. Data were collected by Teague, H.
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Figure 4.7: FO suppressed B-cell stimulated IL-2 secretion from naive CD4+ T 
cells. A: Median fluorescence intensity of CD4+ T cells stained with anti-CD69 and anti-
CD25 after 24 h. CD4+ T cells were stimulated with B cells isolated from mice fed a 
control or FO diet. B: Cytokine secretion after 24 h of activation. Values are means ± 
SEM (n = 6). Asterisk indicates different from control: *P < 0.05. Data were collected by 
Teague, H.
Figure 4.7
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FO enhanced an innate immune response but suppressed an adaptive response. 
Therefore, the data also challenged the paradigm that modification of rafts with FO 
exerts global immunosuppressive effects but overall supported the notion that 
manipulation of immune cell rafts with FO was accompanied by changes in function.
Biochemical measurements revealed some differences between ex vivo and in 
vitro measurements
! The biochemical data from B cells (Figure 4.1) were generally in agreement with 
ex vivo studies, with a few exceptions (143, 211). Fan et al. demonstrated biochemically 
that n-3 PUFAs infiltrated DRMs and DSMs differentially depending on the type of 
headgroup (155). Their data showed the majority of n-3 PUFAs displayed a preference 
for inner leaflet lipids such as PEs. We also found greater incorporation of n-3 PUFAs 
into PEs over PCs. However, Fan et al. reported that n-3 PUFAs incorporated in PE 
DRMs, whereas we observed the majority of n-3 PUFAs in DSMs of PEs (Figure 4.1) 
(155). We also found DHA in PC DRMs, whereas they found no n-3 PUFAs in PC 
DRMs. Finally, we observed an increase in surface levels of GM1, a sphingolipid, 
whereas the same group reported a decrease in SM in a subsequent study (211). The 
differences between the studies could be cell specific or due to differences in diet 
compositions.
! The B cell biochemical data showing DHA incorporated more into DRM PC than 
PE were consistent with model membrane experiments on lipid mixtures containing raft 
molecules (SM and cholesterol). They showed a DHA-containing PC underwent a 
greater increase in molecular order upon adding cholesterol compared with a DHA-
containing PE (Table 4.2). These results were in agreement with previous studies to 
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show cholesterol was more soluble in n-3 PUFAs containing PCs than PEs (152). It is 
also important to note that the DHA-containing PC underwent a substantial increase in 
molecular order when exposed to cholesterol in the mixture with SM, which was 
consistent with the increase in membrane molecular order observed ex vivo when 
comparing cross-linked rafts with the absence of cross-linking with FO (Figure 4.3). 
Although n-3 PUFA acyl chains are highly disordered, very recent data from Mihailescu 
et al. revealed that cholesterol could raise the order of a PC-containing DHA (212). 
Thus, the model membrane data suggest that a PC-containing DHA undergoing an 
ordering effect upon interaction with cholesterol would allow the PC-containing DHA to 
favorably incorporate into rafts.
! Our ex vivo and in vitro data did not concur with some in vitro measurements 
from other labs on cholesterol lateral distribution in DRMs and DSMs. Grimm et al. 
reported that treatment of SH-SY5Y cells with 100 µM DHA increased the normalized 
DSM/DRM ratio (200). We did not observe differences in cholesterol levels between 
DRM and DSMs in B cells or EL4 cells; however, the DRM/DSM ratio tended to be 
lowered in EL4 cells (Supplementary Table 4.2). More work is clearly needed in this 
area because a very recent study reported that treatment of hepatocytes with EPA 
increased raft cholesterol levels, opposite of the findings reported by Grimm and 
coworkers (201).
! There were a few differences between the B cell biochemical data compared with 
the in vitro studies using EL4 cells. The first major difference was that GM1 levels were 
increased ex vivo with FO but not in vitro. The second major difference was that EPA/
DHA did not dramatically infiltrate DRMs ex vivo compared with in vitro. Our in vitro data 
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were in agreement with cell culture studies from other labs (128, 154). For example, 
Stulnig and coworkers showed that treatment of Jurkat T cells with EPA resulted in 
significant incorporation into DRMs and DSMs of SM, PC, and PEs (128). We also 
observed some uptake of n-3 PUFAs into the SM fraction in both cell types, similar to 
Stulnig's lab; however, it is possible that the SM fraction could contain some small 
contaminants from other phospholipids, such as phosphatidylinositols and 
phosphatidylserines.
! Overall, we hypothesize that the differences between our ex vivo and in vitro 
studies were due to differences in cell type (primary vs. immortal) and methods of lipid 
delivery (diet vs. exogenous addition of EPA or DHA). Furthermore, the levels of fatty 
acids (data not shown) and cholesterol (Supplementary Table 4.2) in EL4 cells were 
much higher than B cells, which was not surprising because EL4 cells are dramatically 
larger than primary B cells. Based on a few select experiments, we observed that ∼30% 
of the total n-3 PUFAs incorporated into DRMs of EL4 cells, whereas ∼5–8% of the total 
n-3 PUFAs were in DRMs of primary B cells, generally consistent with previous work 
from our lab and others (150, 209). The significant incorporation of EPA/DHA into DRMs 
in EL4 cells was not due to the dose of fatty acid in culture because even low levels of 
EPA or DHA (5–20 µM) showed the same distribution within error into DRMs and DSMs 
(data not shown).
Imaging demonstrated that FO increased membrane order upon cross-linking
! Detergent extraction is a predictive tool but can induce artifacts (158, 159). An 
alternative method would have been to conduct studies with detergent-free methods to 
isolate rafts (119); however, this was beyond the scope of the study. We discovered, 
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consistent with other studies, that detergent-free methods required a very large number 
of cells (>100 × 106) to isolate rafts (93). Therefore, we relied heavily on imaging to 
determine how FO disrupted raft organization upon CTx-B cross-linking.
! The ex vivo imaging data (Figure 4.2, 4.3) were highly consistent with ex vivo 
data to show that fat-1 mice, which express high endogenous levels of n-3 PUFAs, 
displayed increased molecular order within the CD4+ T-cell immunological synapse 
upon activation with a cognate hybridoma cell relative to nonsynapse regions (140). 
Similarly, we observed that cross-linking GM1 molecules of B cells from FO-fed mice 
had a greater increase in molecular order relative to no cross-linking (Figure 4.3). 
Supporting in vitro studies showed DHA, but not EPA, increased membrane molecular 
order upon cross-linking relative to no cross-linking (Figure 4.5). These results were 
novel because very little is known about the differences in bioactivity between EPA and 
DHA on membrane organization.
! The ex vivo and in vitro imaging data were in agreement with our previous 
studies. We showed previously that treatment of EL4 cells with DHA, but not EPA, 
diminished CTx-B-induced clustering of EL4 cells (150). We also discovered 
administration of a very high dose of a fish/flaxseed oil-enriched diet to mice disrupted B 
cell raft organization with no impact on nonraft organization (187). The data in this study 
provide the first evidence for changes in B cell raft organization with a physiologically 
relevant dose of FO.
Emerging model by which FO increases raft size
! We propose the following working model to explain the ex vivo and in vitro data. 
In the absence of cross-linking, n-3 PUFA incorporation into the membrane, either 
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through the diet or in culture, decreased membrane order due to the highly disordered 
nature of the n-3 PUFA acyl chains (105). In vivo, FO also enhanced GM1 surface 
levels, which could be due to targeting of GM1 biosynthesis and/or trafficking to the 
plasma membrane. Although the GM1 molecules were poised to form rafts in the 
absence of cross-linking, they were not in a state where large-scale phase separation 
could be observed (213, 214).
! Upon cross-linking CTx-B, the membrane became more ordered as lipid 
molecules were forced together and micron-scale domains became visible with FO. We 
speculate that FO administration resulted in the trapping of n-3 PUFAs into the large-
scale raft domains. Cholesterol was not displaced out of the rafts in either model 
system. Instead, the mixing of cholesterol with n-3 PUFAs had an ordering effect on the 
membrane, as demonstrated with model membrane studies. In vitro studies 
demonstrated that the effects on membrane order were driven by DHA rather than by 
EPA. Overall, our data supported the model that FO can exert an ordering effect as 
opposed to the other models discussed above (140).
Disruption of rafts with FO was accompanied by differential effects on innate and 
adaptive B cell functions
! The previous work on how FO disrupts rafts and the subsequent impact on 
immune cell function has centered on CD4+ T cells, macrophages, and splenocytes 
(140, 142, 143). Generally, manipulation of lipid microdomain organization (which may 
have utility as a biomarker of n-3 PUFA manipulation) with n-3 PUFAs was reported to 
be accompanied by immunosuppression. Here we discovered that LPS stimulation of B 
cells increased cytokine secretion (Figure 4.6). The data were similar to a few studies 
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showing that activation of splenic macrophages with LPS resulted in increased cytokine 
secretion with FO (73, 215, 216). The data were also in agreement with our previous 
report showing that very long-term administration of a high–fat, fish/flaxseed oil-
enriched diet enhanced activation of B cells (160). We had previously suggested that 
the increase in B cell activation was due to body weight gain, which we now know is not 
the driving factor.
! The functional data (Figure 4.6) were not entirely in agreement with some in vitro 
studies showing that DHA suppressed LPS activation of macrophages and dendritic 
cells (68, 217, 218). This could be due to aforementioned differences (e.g., cell type, 
diet vs. in vitro treatment, etc.). Increased proinflammatory cytokine secretion does not 
allow us to conclude that FO is proinflammatory. It is possible that increased B cell 
activation could have potential clinical utility, especially in terms of antibody production. 
A few labs have studied the impact of FO on antibody production with mixed results 
(219-222). Altogether, these data highlighted the notion that FO is not universally 
immunosuppressive.
! The antigen presentation data were the first to demonstrate that dietary 
manipulation of B cells with FO suppressed naive T-cell activation (Figure 4.7). Our data 
confirmed several in vitro studies that showed EPA and/or DHA treatment of B cells, 
dendritic cells, and monocytes/macrophages diminished antigen presentation to 
cognate T cells (162, 223). The data were also consistent with one ex vivo study 
demonstrating a mixture of antigen-presenting cells (B cells, macrophages, dendritic 
cells) isolated from a DHA-enriched diet suppressed the proliferation of naive CD4+ T 
cells from mice fed control diets (224).
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! The functional data open the door to a wide range of new targets and 
mechanisms by which FO differentially affects B cell function. The mechanisms 
downstream of the plasma membrane by which n-3 PUFAs enhance B cell activation 
will require studying complex signaling pathways and their impact on gene activation. In 
the case of the antigen presentation studies, we now for the first time raise the 
possibility that lipid manipulation of the B cell side of the immunological synapse may be 
a major contributing factor by which T-cell activation was suppressed with n-3 PUFAs. It 
will be interesting to determine how manipulation of lipid microdomains can lead to an 
immune-enhancing effect with LPS and to a suppression of function when interacting 
with a T cell. It was beyond the scope of this study to address this, but it is something 
we aim to pursue in order to develop FO as a therapeutic agent for chronic 
inflammation.
Conclusion
! We demonstrated that a physiologically relevant dose of FO increased the size of 
B cell rafts, GM1 surface expression, and membrane molecular order upon cross-linking 
CTx-B. Supporting in vitro studies suggested that the effects on membrane order were 
driven by DHA but not EPA. Furthermore, the B cell data supported an emerging model 
that increasing raft size with FO was accompanied by changes in innate and adaptive 
function. Overall, the results established the utility of using a relevant dose of FO for the 
first time to target B cell microdomain clustering and cellular function.
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CHAPTER 5: MHC CLASS II ORGANIZATION ON THE B CELL SIDE OF THE 
MURINE IMMUNOLOGICAL SYNAPSE IS DISRUPTED BY DIETARY N-3 
POLYUNSATURATED FATTY ACIDS
Introduction
! n-3 PUFAs are unique bioactive molecules with emerging health benefits and 
clinical applications for treating acute and chronic inflammatory diseases (1). In 
particular, EPA and DHA, the major n-3 PUFAs of fish oil, are increasingly recognized as 
regulators of both innate and adaptive immunity (2). EPA and DHA exert their functional 
effects on immunity at a cellular level through several mechanisms. One central but 
poorly studied mechanism of these fatty acids is to disrupt the lateral organization of 
plasma membrane lipid-protein molecules that facilitate efficient intracellular signaling or 
cell-cell communication (225). In this study, we focused on the mechanistic effects of 
fish oil on the immunological synapse, a highly organized membrane domain formed 
between APCs and T cells that is critical for immune responses (131, 133).
! A series of studies over the past decade have established that n-3 fatty acids in 
fish oil disrupt lipid microdomain composition and protein lateral distribution of naïve 
CD4+ T cells in order to suppress downstream activation. For example, administration of 
dietary fish oil to mice suppressed recruitment of T cell PKCθ into lipid raft 
microdomains and subsequent IL-2 secretion when activated with anti-CD3/28 
antibodies (211). Likewise, in vitro treatment of Jurkat T cells with EPA diminished 
recruitment of signaling proteins to the immunological synapse when mixed with 
untreated antigen loaded APCs (139). Similar results were also reported with ex vivo 
studies using CD4+ T cells from fat-1 transgenic mice that endogenously produce n-3 
PUFAs (140, 141). In contrast, very little is known about the effects of fish oil on the 
molecular organization of proteins on the APC side of the immunological synapse.
! B cells can serve as APCs in addition to their canonical role as antibody 
producing cells (84, 85). MHC class II proteins on the surface of B cells present 
antigens to CD4+ T cells by clustering at the site of the immunological synapse (226). 
Our lab has previously shown that B cells, isolated from mice fed a physiologically 
relevant dose of fish oil, suppressed IL-2 secretion from CD4+ T cells compared to a 
control diet (227). Furthermore, the functional changes were accompanied by 
diminished clustering of cholera-toxin induced GM1 microdomains with fish oil on the B 
cell plasma membrane. Our functional data were highly consistent with other studies 
that show fish oil administration to mice can indirectly suppress naïve CD4+ T cell 
activation by targeting accessory cells including macrophages, dendritic cells and B 
cells (72, 224, 228).
! In this study, we tested the hypothesis that dietary fish oil disrupts B cell MHC 
class II clustering and localization to the immunological synapse, a potential mechanism 
by which fish oil suppresses CD4+ T cell activation. We studied the impact of fish oil on 
murine MHC class II lateral organization in the absence and presence of the formation 
of the immunological synapse using a combination of imaging methods. We compared 
the magnitude of the effects of fish oil with two well-described pharmacological reagents 
known to disrupt protein lateral organization (229, 230). We used methyl-beta-
cyclodextrin (MβCD) to deplete cellular cholesterol and cytochalasin D to prevent actin 
polymerization. Our data reveal a novel mechanism of fish oil and show for the first time 
that dietary lipids manipulated the APC side of the immunological synapse.
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Experimental Procedures
Mice and cells
! Male C57BL/6 mice (Charles River), 4–6 weeks old, were fed for 3 weeks a 
purified 5% total fat by weight control or fish oil diet (Harlan-Teklad) as previously 
described (227). The mouse fish oil diet models human intake of approximately 4 grams 
of fish oil per day, which is in use clinically for treating elevated triglycerides (52). Mice 
were euthanized using CO2 inhalation and cervical dislocation. B220+ B cells were 
isolated from the spleens of the C57BL/6 mice and CD4+ T cells were isolated from OT-
II transgenic mice as previously shown (227). All of the experiments with mice fulfilled 
the guidelines established by the East Carolina University Brody School of Medicine for 
euthanasia and humane treatment.
GC
! Total lipids were extracted from B cells and the fatty acid composition was 
analyzed by GC as previously described (160). Areas of identified peaks were summed 
and each peak area is expressed as the percentage of total peak area for each sample. 
Only the major fatty acids are reported for simplicity.
Reagents and antibodies
! M5/114 MHC class II antibody (BioXCell) was conjugated to either Cy3 or Cy5 
using a standard fluorophore conjugation kit (GE Healthcare). For some experiments, B 
cells were treated for 15 min with 10 mM MβCD (Sigma) or 2 µg/mL cytochalasin D 
(Sigma). α-FITC-CD3ε molecular complex (BD Biosciences), goat-α-PKCθ (Santa 
Cruz), and α-goat Alexa Fluor 633 (Invitrogen) were used for immunological synapse 
staining.
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TIRF microscopy and analysis
! 6.25 x 105 B220+ B cells were adhered to glass cover slips (Corning) coated with 
poly-D-lysine (Sigma) and then fixed with 4% paraformaldehyde (Electron Microscopy 
Sciences). For cells treated with MβCD and cytochalasin D, cells were first adhered and 
then treated. Cells were stained with anti-MHC class II antibody and mounted onto 
slides. TIRF microscopy was preformed as shown in a recent study by our lab (227). 
TIRF images were acquired at a penetration depth of 100 nanometers. Approximately 
10 cells per experiment were analyzed for each treatment or diet using NIH ImageJ 
(http://rsbweb.nih.gov/ij/). The number of clusters and average cluster size was 
determined by creating a region of interest within a cell, confirmed by DIC, followed by 
setting a threshold to analyze particles.
FRET microscopy and analysis
! MHC class II FRET was measured in terms of the efficiency of energy transfer 
from donor (Cy3) to acceptor (Cy5) fluorophores as previously described (187). Briefly, 
B cells were fixed with 4% paraformaldehyde and then stained with separately labeled 
Cy3 and Cy5 MHC class II antibodies. Cells were imaged on a Zeiss LSM 510 before 
and after photobleaching the acceptor fluorophore. All images were analyzed using NIH 
ImageJ and the FRET calc plugin for acceptor photobleaching FRET (172). Positive 
control images were generated using a single antibody dual labeled with both donor and 
acceptor. Negative control images were generated to optimize photobleaching time by 
using only single colors.
Immunological synapse staining and analysis
! To form immunological synapses, B cells were first incubated with 10-5 M OVA323–
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339 peptide (GenScript) for 1 hour at 37°C. Peptide loaded B cells from C57BL/6 mice 
(either from diet modified mice or treated with pharmacological agents) and CD4+ T cells 
from OT-II transgenic mice were then mixed (1:2) and briefly spun down on a bench-top 
centrifuge. Cell-cell conjugates were subsequently transferred to poly-D-lysine coated 
coverslips and incubated at 37°C for 30 min. Additional time points were tested for 
select experiments. The cells were then fixed with 4% paraformaldehyde, permeabilized 
with 0.2% Triton X-100 (Sigma) and blocked overnight in PBS with 2% fatty acid free 
BSA at 4°C. Cells were stained for key immunological synapse markers.
! Images were acquired on a Zeiss LSM 510 or an Olympus IX-81 FV1000 
confocal microscope. Scoring of protein patching at the immunological synapse was 
performed as described by others (140, 231, 232). The cells were scored by BDR and 
SRS. The percentage of B cells forming B-T conjugates was also calculated from the 
same set of images.
Statistics
! Reported values are means ± SEM from several independent experiments. All 
statistical analyses were calculated using GraphPad Prism (GraphPad Software). Select 
experiments for measuring the recruitment of molecules into the immunological synapse 
were performed blinded to ensure lack of bias. All the data sets were verified for 
normality. For experiments when two treatments were performed compared to a control, 
significance was determined by a one-way ANOVA followed by Dunnett’s post-hoc t test. 
For all other experiments, significance was established by a two-tailed t test. P-values < 
0.05 were considered significant.
Results
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Fish oil increases B cell EPA and DHA levels
! Prior to initiating studies on MHC class II organization, we first ensured that the 
fish oil diet increased murine B cell levels of EPA and DHA. GC analysis revealed the 
fish oil diet significantly increased 16:1 levels by 75% compared to the control. EPA, 
20:5 n-3, and its elongation production 22:5 n-3 were both increased relative to the 
control by 760% and 260%, respectively (Table 5.1). DHA, 22:6 n-3, levels increased by 
66% with the fish oil diet compared to the control. This resulted in a 124% increase of 
total n-3 PUFA fatty acid levels with the fish oil diet. Conversely, there was a 36% 
decrease in 20:4 (n-6) and a 27% decrease in total n-6 PUFA fatty acid levels with the 
fish oil diet compared to the control (Table 5.1). The n-6/n-3 ratio was significantly 
decreased from 4.1 for the control diet to 1.5 for the fish oil diet (Table 5.1). These data 
are in agreement with our previous findings to show fish oil increases total B cell n-3 
PUFA levels at the expense of n-6 fatty acids (227).
Fish oil has no impact on B cell MHC class II organization in the absence of an 
immunological synapse
! MHC class II is expressed in clusters on the plasma membrane surface of B cells 
(233, 234). Therefore, we addressed if dietary fish oil disrupts B cell MHC class II IAb 
clustering prior to the formation of the immunological synapse. Using TIRF microscopy, 
we visualized MHC class II protein clustering on the plasma membrane surface (Figure 
5.1A). B cells isolated from mice fed the fish oil diet showed no change in average 
cluster quantity compared to the control (Figure 5.1B). We also measured MHC class II 
protein distribution on the nanoscale using acceptor photobleaching FRET microscopy. 
Again, there was no significant difference in FRET efficiency of MHC class II molecules 
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Table 5.1: Fatty acid analysis of B cells
Fatty Acid Control Fish Oil
14:0 0.6 ± 0.2 1.0 ± 0.2
16:0 26.9 ± 0.9 28.2 ± 0.9
16:1 1.2 ± 0.1 2.1 ± 0.2***
18:0 26.2 ± 3.8 24.9 ± 2.6
18:1 trans 0.5 ± 0.2 0.6 ± 0.2 
18:1 cis 11.8 ± 1.8 10.9 ± 1.5
18:2 (n-6) 13.4 ± 2.8 8.3 ± 2.5
18:3 (n-6) 1.3 ± 0.4 4.3 ± 2.3
18:3 (n-3) 1.2 ± 0.4 0.9 ± 0.3
20:4 (n-6) 10.6 ± 1.0 6.7 ± 0.4**
20:5 (n-3) 0.5 ± 0.4 4.3 ± 0.6***
22:5 (n-3) 0.8 ± 0.1 2.9 ± 0.3***
22:6 (n-3) 3.5 ± 0.4 5.8 ± 0.7*
∑SFA 53.7 ± 3.9 54.0 ± 3.2
∑MUFA 13.5 ± 1.9 13.5 ± 1.6
∑PUFA (n-6) 25.2 ± 2.0 18.3 ± 2.3*
∑PUFA (n-3) 6.2 ± 0.4 13.9 ± 1.4***
n-6/n-3 4.1 ± 0.3 1.5 ± 0.4***
Fatty acids were extracted from the diets and analyzed with gas chromatography. 
Values are the percentage of total fatty acids. Values less than 0.5 are omitted for 
clarity. Asterisks indicate different from control: *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 5.1: Fish oil diet has no effect on B cell MHC class II lateral organization 
prior to synapse formation. A) Representative TIRF images of MHC class II molecules 
on B cells isolated from mice fed control (left) or fish oil (right) diets. Scale bar 
represents 5 microns. B) Quantification of the number of B cell MHC class II clusters in 
a given region of interest from control (white) and fish oil (black) fed mice. C) FRET 
efficiency for MHC class II molecules from control (white) and fish oil (black). Values in 
B are means ± SEM (n = 5 with 110 - 111 cells analyzed per diet). Values in C are 
means ± SEM (n = 4 with 39-40 cells analyzed per diet). Data in A-B were collected by 
Melton, M.
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on the B cell surface between the fish oil diet compared to the control (Figure 5.1C). 
There was also no change in the surface expression of MHC class II molecules on B 
cells from the fish oil diet as measured with microscopy and flow cytometry (data not 
shown).
Pharmacological agents disrupt B cell MHC class II organization in the absence of 
an immunological synapse
! We next tested the sensitivity of MHC class II organization by treating B cells with 
pharmacological agents known to disrupt protein organization (233, 235-237). We again 
used TIRF microscopy to visualize MHC class II protein clustering. Figure 5.2A shows 
representative images of B cell MHC class II clustering from control cells and those 
treated with MβCD or cytochalasin D. The number of MHC class II clusters was 
decreased by 42% with MβCD treatment (Figure 5.2B). In contrast, cytochalasin D 
treatment had no effect on the average number of clusters per region of interest. On the 
nanometer scale, MβCD treatment did not modify FRET efficiency (Figure 5.2C). 
However, cytochalasin D treatment of B cells decreased FRET efficiency between MHC 
class II molecules by 20% compared to the control. Treatment of B cells with MβCD or 
cytochalasin D was not associated with any change in the surface expression of MHC 
class II molecules (data not shown). Taken together, the micron and nanoscale 
measurements revealed that the B cell plasma membrane MHC class II organization 
was sensitive to changes in lateral organization with pharmacological agents, albeit in 
different ways.
Naïve B and naïve T cells form a stable immunological synapse after 30 minutes 
of conjugation
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Figure 5.2: Cholesterol depletion and actin disruption reveal differential effects on 
MHC class II clustering. A) Representative TIRF images of MHC class II from control, 
MβCD, or cytochalasin D treated B cells. Scale bar represents 5 microns. B) 
Quantification of the number of MHC class II clusters in a region of interest from TIRF 
microscopy for control (white) and treatment (black). C) FRET efficiency for MHC class 
II molecules from control (white) and treatment (black). Values are means ± SEM (n = 3 
with 30 - 50 cells analyzed per treatment). Asterisks indicate different from control: *P < 
0.05; ***P < 0.001. Data in A-B were collected by Melton, M.
! The next goal was to determine the effect of fish oil and pharmacological agents 
on MHC class II lateral organization in the immunological synapse. Due to the novelty of 
investigating murine naïve B-naïve T synapse formation, the kinetics of synapse 
formation within this model system were first determined. We measured the patching of 
key proteins at the immunological synapse as a function of conjugation time. 
Representative images were acquired for B cell MHC class II and T cell CD3ε and 
PKCθ over time (Figure 5.3A). There was a 90% increase in MHC class II patching after 
30 minutes, as well as a 100% increase at 45 minutes of conjugation compared to 5 
minutes (Figure 5.3B). CD3ε patching peaked at 30 minutes, increasing by 250% 
compared to 5 minutes (Figure 5.3C). PKCθ patching plateaued at 30-45 minutes, 
increasing by 100% compared to 5 minutes (Figure 5.3C). Therefore, we selected 30 
minutes of conjugation time for the next set of experiments since this time point 
provided the highest percentage of patching for all markers tested.
Fish oil decreases B cell MHC class II and cognate CD4+ T cell PKCθ recruitment 
to the immunological synapse independent of changes in cell-cell adhesion
! We next tested the hypothesis that in the immunological synapse, fish oil would 
disrupt MHC class II recruitment. B cells from mice fed fish oil or control diets were 
loaded with peptide and mixed with CD4+ T cells to stimulate formation of immunological 
synapses. Representative images of MHC class II, CD3ε and PKCθ staining are shown 
in Figure 5.4A. MHC class II patching in the synapse was decreased by 15% with the 
fish oil diet compared to the control (Figure 5.4B). In addition, FRET microscopy 
revealed a trend (P=0.07) in lowering FRET efficiency for MHC class II molecules 
(Figure 5.4C).
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Figure 5.3: Localization of B and T cell molecules at the immunological synapse 
as a function of conjugation time. A) Representative DIC (left) and 
immunofluorescent confocal images of MHC class II (yellow), CD3ε (green), and PKCθ 
(red) at the immunological synapse after 5, 15, 30, and 45 min of incubation. Scale bar 
represents 5 microns. B) Quantification of the percentage of conjugated B and T cells 
displaying patching of MHC class II at the immunological synapse over time. C) Percent 
patching of CD3ε (grey) and PKCθ (black) at the immunological synapse over time. 
Values are means ± SEM (n = 3 - 4 with 42 - 63 cells analyzed per diet). Asterisks 
indicate different from 5 min: **P < 0.01.
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Figure 5.4: Fish oil disrupts the B-T cell immunological synapse. A) Representative 
DIC (left) and immunofluorescent confocal images of MHC class II (yellow), CD3ε 
(green), and PKCθ (red) at the immunological synapse. B cells were isolated from mice 
fed a control (top) or fish oil (bottom) diet. Scale bar represents 5 microns. B) Percent 
patching of MHC class II at the immunological synapse for B cells from control or fish oil 
fed mice. C) FRET efficiency for MHC class II molecules at the site of the immunological 
synapse from control and fish oil fed mice. D) Percent patching of CD3ε and PKCθ at 
the immunological synapse. The B cells are from control or fish oil fed mice and T cells 
are from OT-II transgenic mice fed a standard chow. E) Percentage of B cells from 
control or fish oil fed mice that conjugate with CD4+ T cells. Values in B, D - E are 
means ± SEM (n = 4 with 129 - 146 cells analyzed per diet). Values in C are means ± 
SEM (n = 4 with 35 cells analyzed per diet). Asterisks indicate different from control: *P 
< 0.05; ***P < 0.001.
! To address the impact of the change in MHC class II organization with fish oil on 
the T cell side, we measured patching of CD3ε and PKCθ at the immunological 
synapse. CD3ε organization was unmodified by the fish oil diet. However, PKCθ 
patching decreased 27% with fish oil (Figure 5.4D). We confirmed the percentage 
patching data by also measuring the fluorescent intensity values of the staining for each 
marker inside the synapse region compared to the non-synapse region (Supplemental 
Figure 5.1 A,C). We then computed the ratio of the staining synapse/non-synapse 
(Supplemental Figure 5.1B,D). These changes in protein localization were not a 
consequence of decreased conjugate formation, as there was no significant difference 
in the percentage of B cells forming conjugates with T cells (Figure 5.4E).
! Given that previous studies have shown that EPA and/or DHA treatment can 
suppress cell-cell adhesion in vitro, we performed a static cell adhesion assay on B cells 
from the control and fish oil fed mice (139, 162). The ability of B cells to bind 
immunological synapse adhesion proteins VCAM-1, ICAM-1, ADAM28, and the 
extracellular matrix protein fibronectin was not modified by the fish oil diet (data not 
shown). Overall, these data show fish oil can modify MHC class II lateral organization 
and indirectly manipulate PKCθ lateral organization in the synapse. 
Pharmacological agents disrupt B and T cell protein organization in the 
immunological synapse similar to fish oil
! Finally, we compared the effects of fish oil on the formation of the immunological 
synapse with MβCD and cytochalasin D treatment to B cells. Representative 
immunofluorescence images of MHC class II, CD3ε, and PKCθ are shown in Figure 
5.5A. MβCD treatment of B cells decreased MHC class II patching by 23% (Figure
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Figure 5.5: Pharmacological agents disrupt the B-T cell immunological synapse. 
A) Representative DIC (left) and immunofluorescent confocal images of MHC class II 
(yellow), CD3ε (green), and PKCθ (red) at the immunological synapse from control 
(top), MβCD (middle), or cytochalasin D (bottom) treated B cells. Scale bar represents 5 
microns. B) Percent patching of MHC class II at the immunological synapse for control 
(white), MβCD (grey), or cytochalasin D (black) treated B cells. C) FRET efficiency for 
MHC class II molecules from control, MβCD, or cytochalasin D treated B cells. D) 
Percent patching of CD3ε and PKCθ at the immunological synapse for control, MβCD, 
or cytochalasin D treated B cells. E) Percentage of control, MβCD, or cytochalasin D 
treated B cells that conjugate with CD4+ T cells. Values in B, D-E are means ± SEM (n = 
3 with 117 - 166 cells analyzed per treatment). Values in C are means ± SEM (n = 3 with 
30 cells analyzed per treatment). Asterisks indicate different from control: *P < 0.05; **P 
< 0.01; ***P < 0.001.
 5.5B). Cytochalasin D treatment showed a trend in the reduction in MHC class II 
patching (P=0.06) (Figure 5.5B). We next measured FRET efficiency of MHC class II 
molecules at the synapse. Interestingly, despite lower localization at the synapse, 
MβCD treatment increased MHC class II FRET efficiency by 174% compared to the 
control (Figure 5.5C). Cytochalasin D treatment did not impact FRET efficiency at the 
synapse (Figure 5.5C).
! Similar to fish oil, treatment of B cells with MβCD and cytochalasin D also 
diminished protein patching on the T cell side of the immunological synapse. CD3ε 
patching was unchanged by MβCD treatment (Figure 5.5D). However, cytochalasin D 
treatment of B cells decreased CD3ε patching by 95% compared to control (Figure 
5.5D). MβCD and cytochalasin D treatment both reduced patching of PKCθ at the 
synapse by 20% and 26% respectively (Figure 5.5D). We also confirmed the 
percentage patching data here also by measuring the fluorescent intensity values of the 
staining for each marker inside the synapse region compared to the non-synapse region 
(Supplemental Figure 5.2 A,C). We then computed the ratio of the staining synapse/
non-synapse (Supplemental Figure 5.2 B,D). Although protein localization was 
disrupted, the percent of cells that formed conjugates was not modified by either 
treatment (Figure 5.5E). These data reveal that pharmacological treatment of B cells 
disrupts the organization of immunological synapse proteins on both the B and T cell 
side of the immunological synapse, similar to the fish oil diet.
Discussion
! In this study we establish that fish oil-mediated disruption of B cell MHC class II 
organization at the immunological synapse can translate into an effect on T-cell 
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membrane organization. Our data show for the first time that fish oil can target the APC 
side of the immunological synapse in a manner similar to that reported for the effects of 
fish oil on T cells (139-141, 211). This work significantly expands our understanding of 
how fish oil, compared to other pharmacological agents, can target the molecular 
organization of B cells. Furthermore, our data establish a role for dietary lipids on the 
APC side of the synapse.
The APC side of the immunological synapse
! Although the literature is replete with investigations on how fish oil modulates the 
organization of the synapse, the work-to-date has focused on the T cell side and far less 
is known about the molecular organization of the APC side, in particular the B cell 
component (238). Our findings underscore the impact of manipulating specifically B 
cells through dietary means on the formation of the immunological synapse. Our 
rationale for focusing on B cells was driven by our previous data to show that 
administration of fish oil to mice suppressed B cell mediated activation of naïve T cells. 
We did pursue select studies with CD11c+ dendritic cells (DC) and discovered that 
activated DCs did not affect on naïve T cell activation; furthermore, fish oil had no effect 
on DC lipid-protein microdomain organization (data not shown, manuscript in review).
! Peptide loaded clusters of MHC class II complexes are critical for initiating T cell 
activation (233). Even a single MHC–peptide complex can trigger a Ca2+ signal and a 
mature synapse can be formed when approximately 10 complexes are present (239). 
However, what is unclear is how the underlying lipid composition controls MHC class II 
organization and its impact on the formation of the synapse on the T cell side. To date, a 
few other studies have previously suggested that membrane lipids have a role in 
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disrupting the APC side of the synapse (162, 240). For example, Fooksman et al. 
showed that the concentration of PI(4,5)P2 at the synapse regulated APC function (240). 
Sequestration of PI(4,5)P2 upon transfection with specific constructs in mouse and 
human B cells prevented the APCs from effective recognition by cognate T cells. These 
effects were likely tied to changes in the organization of the cytoskeleton. Recently, 
myosin 1c was identified to be co-localized with MHC class II molecules and recruited 
on the B cell side of the synapse (241). Our data demonstrate that dietary composition 
influences the APC side of the synapse, and indirectly alters the T cell side by targeting 
MHC class II.
! Some studies suggest that naïve B cells do not efficiently activate naïve T cells or 
do so only under certain circumstances (242, 243). Due to this limitation, we felt that it 
was imperative to establish the time course of naïve B-naïve T cell synapse formation. 
In our model system, we found the maximum amount of MHC class II and PKCθ 
localized at the synapse after 30 minutes of conjugation. Watson et al. also found 
maximal PKCθ localization at 30 minutes with naïve APCs and naïve T cells in a similar 
transgenic system with BALB/c mice (231). However, the population of APCs used in 
their study was splenocytes and not purified B cells. Another study also reported the 
formation of a mature synapse using human naïve B and naïve T cells, but the kinetics 
were not reported (138).
Fish oil versus pharmacological disruption of the lateral organization of MHC 
class II in the absence of the synapse
! MHC class II organization is critical for immunological synapse formation and its 
function is dependent on the residing lipid environment (244). MHC class II molecules 
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reside in lipid raft-like domains to enhance antigen presentation to T cells (245, 246). 
Some have even proposed that newly synthesized MHC class II molecules are 
trafficked to lipid raft domains prior to antigen loading (247). Since we previously 
demonstrated that fish oil diminished B cell lipid microdomain clustering induced by 
cholera toxin cross-linking (227), we expected MHC class II organization would be 
disrupted with n-3 fatty acids (in the absence of a synapse). However, contrary to our 
expectation, our data showed no effect of fish oil on the lateral organization of MHC 
class II molecules prior to the formation of an immunological synapse. Perhaps, we 
were unable to detect subtle changes considering that a fraction of MHC class II 
molecules are pre-clustered on the B cell surface (248). However, another study 
showed that primary B cells displayed MHC class II clustering upon exposure to antigen 
(234). Our data support this notion, as we observed no changes in MHC class II lateral 
organization in the absence of antigen.
! Given that little is known about the molecular organization of the APC side of the 
synapse, we compared the effects of fish oil to known disrupters of membrane 
organization. Treatment of B cells with pharmacological agents provided varying results 
on MHC class II organization. Previously, Vrljic et al. showed that removal of cholesterol 
with MβCD decreased MHC class II diffusion (235). Our TIRF data appear to be in 
agreement with this study. Removing cholesterol from the plasma membrane generates 
solid-like domains (containing lipids with a high melting temperature) (235). This 
process slows protein diffusion and limits the number of protein clusters dispersed on 
the plasma membrane. The actin cytoskeleton also serves a role in clustering or 
corralling molecules on the plasma membrane surface. It was previously demonstrated 
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that cytochalasin D treatment of B cells did not change the lateral organization of MHC 
class II molecules (233). Umemura et al. explains this by showing that MHC class II 
actually undergoes hop diffusion in the plasma membrane (249). Our data suggest that 
the cytoskeleton may impact nanoscale spatial distribution of MHC class II molecules 
but may not completely remodel the surface organization observed at the micron scale. 
Taken together, our data show that in the absence of the synapse, fish oil and 
pharmacological agents have distinct effects on B cell MHC class II organization.
Fish oil, similar to pharmacological agents, inhibits the ability of B cells to 
organize MHC class II molecules at the immunological synapse
! Although we previously reported B cells isolated from mice fed a fish oil diet 
suppressed T cell IL-2 secretion (227), we did not investigate the underlying mechanism 
at the level of the immunological synapse. Our data suggest the downstream functional 
effects reported previously by our lab and others are driven, in part, by an inability of 
MHC class II molecules to recruit to the synapse and thereby prevent recruitment of 
PKCθ, which is an early marker for stable formation of an immunological synapse (132).
! We did not observe an effect of fish oil on B cell adhesion or surface expression 
of MHC class II (data not shown). It was previously reported that human B lymphoblasts 
treated with DHA in vitro could evade lysis by alloreactive human CD8+ T cells as a 
result of an inability to conjugate (162). Similarly, Stulnig and co-workers reported that 
EPA treatment of T cells could suppress the formation of the synapse by diminishing 
APC-T cell conjugation (128). Furthermore, fish oil supplementation in humans was 
shown to decrease the expression of adhesion molecules and MHC class II levels in 
monocytes, which prevented antigen presentation to autologous lymphocytes (70, 250). 
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Therefore, we conducted extensive studies on B cell adhesion to known ligands (data 
not shown) and found no effect of fish oil. Furthermore, we conducted select studies in 
which we treated immortal Raji B cells with n-3 fatty acids and indeed discovered that 
cell adhesion with Jurkat T cells was suppressed in vitro (data not shown). Thus, we 
reconcile our data with those of others based on differences between treatment in cell 
culture and administration of dietary fish oil to animals.
! We relied on pharmacological agents to disrupt B cells to compare with the 
effects of fish oil. Although there were differential effects on MHC class II clustering prior 
to synapse formation, both MβCD treatment and dietary manipulation of B cells resulted 
in diminished localization of MHC class II and PKCθ at the immunological synapse. This 
finding is consistent with evidence that treatment of either B or T cells with MβCD 
results in inhibition of T cell activation (251-253). Likewise, cytoskeletal disruption of B 
or T cells similarly results in inhibition of T cell activation (252, 254, 255). Although we 
did not find a statistically significant reduction in MHC class II localization to the synapse 
with cytochalasin D treatment, we did observe a trend (P=0.06). Pharmacological 
disruption of membrane organization appears to have a similar functional impact on 
synapse protein localization to that of fish oil.
Fish oil suppresses T cell activation by targeting both B and T cells
! Figure 5.6 shows how fish oil impacts both B and T cells during the formation of 
the immunological synapse. Shown in red are results from this study (Figure 5.6). Fish 
oil modifies the composition of the B cell plasma membrane and directly suppresses 
MHC class II localization and thereby prevents PKCθ recruitment into the 
immunological synapse (Figure 5.6). Shown in blue are results from previous studies 
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Figure 5.6: Fish oil suppresses CD4+ T cell activation by targeting both B and T 
cells. MHC class II proteins localize to the immunological synapse on the surface of B 
cells (top) to present antigen to T cells (bottom). CD3ε and PKCθ localize to the 
immunological synapse in response to antigen stimulation by the APC, ultimately 
promoting downstream cytokine secretion. The cumulative work from this study and 
those of others show fish oil can block the process of CD4+ T cell activation by targeting 
molecular organization of both B cells (shown in red) and T cells (shown in blue).
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from other labs focusing on the impact of n-3 fatty acids on T cells (Figure 5.6) (139, 
140). For instance, Kim et al. show that fat-1 mouse CD4+ T cells have reduced PKCθ 
localization to the site of CD3/CD28 binding (140). The same group later showed that 
mitochondrial localization and subsequent calcium signaling was also impaired by n-3 
fatty acids in the same model system (141). Combined with our previous findings of 
reduced T cell activation by B cells and those of others on the T cell side, we propose 
that fish oil exerts very similar effects on the both sides of the synapse to suppress T 
cell activation (Figure 5.6) (139-141).
! In summary, our data demonstrate a novel mechanism to explain how fish oil 
suppresses T cell activation. We specifically demonstrate that fish oil can target MHC 
class II organization in the synapse, which has an impact on the T cell side. 
Furthermore, this is the first evidence demonstrating that the molecular organization of 
the APC side of the immunological synapse is sensitive to dietary fish oil lipids. This 
work significantly expands our understanding of how fish oil, modeling current clinical 
use, can exert immunosuppressive effects.
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CHAPTER 6: CONCLUSIONS
Overview
! Using various high and low fat n-3 PUFA mouse diet models, we have 
established how n-3 PUFAs can target lipid-protein organization and thereby B cell 
antigen presentation. In doing so, we have advanced the field of n-3 PUFAs in a number 
of areas. We demonstrated that a physiologically relevant dose of fish oil dispersed 
clustering of B cell lipid rafts on a micron scale, and enhanced membrane molecular 
order upon cross-linking CTx-B. We found that the effects on lipid rafts are primarily 
driven by DHA and not EPA, and that n-3 PUFAs have a limited influence on non-raft 
lateral organization. We also demonstrate reduced activity when consuming very high 
doses of n-3 PUFAs. Finally, we show that fish oil suppresses B cell antigen 
presentation and subsequent CD4+ T cell IL-2 secretion, by disrupting the B cell side of 
the immunological synapse. While we have not solved all the mechanisms for how fish 
oil can exert immunosuppressive effects on B cells, we have demonstrated that plasma 
membrane lateral organization plays a critical role in this process.
The challenge of studying lipid rafts
! A major limitation for studying lipid rafts is the lack of clear evidence for the 
specific structure and function of these membrane domains (114). Detergent extraction 
has some success as a predictive tool for which proteins may be localized to lipid raft 
domains, but this method is also very prone to inducing artifacts because of the harsh 
nature of detergents (158, 159). In Chapter 4 we used detergent extraction and HPLC/
GC methods to determine the alteration in phospholipid acyl chain profile upon fish oil 
consumption. However, in Chapters 2, 4 and 5, we also relied heavily on a combination 
of imaging techniques, such as FRET, TIRF, and generalized polarization, to support our 
findings from the lipid extraction and biochemical techniques. Mass spectrometry and 
other advances in lipidomics will give additional details about novel acylation of lipids or 
proteins by EPA/DHA. These added resources would provide tremendous benefit for 
finding new targets that may provide better insight into how fish oil disrupts lipid raft 
clustering. Here our studies provided clear visual evidence that fish oil disrupts plasma 
membrane domains of B cells, and we have gained some insight into how this 
disruption occurs.
DHA, a distinct disrupter of raft clustering!
! EPA and DHA do not behave identically in targeting the plasma membrane. In 
Figure 4.5, we show that DHA has a much more dramatic effect on plasma membrane 
molecular order than EPA. We also have previously shown that treatment of EL4 cells 
with DHA, but not EPA, disrupted lipid raft clustering (150). The Fenton lab has since 
confirmed this finding in animals through specific mouse diet models (manuscript in 
preparation). One explanation for this may be that, when DHA is incorporated into PCs, 
it is twice as likely as EPA to localize in a raft-like domain (256). Inside a raft domain, 
without a stimulus to preserve the molecular packing and order, the highly dynamic 
biophysical properties of DHA would displace cholesterol and proteins. However, most 
DHA and EPA incorporate into PEs, which localize primarily on the inner leaflet of the 
plasma membrane in non-raft like domains (Figure 4.1). Yet, as we have shown in 
Chapter 2, non-raft proteins are not as sensitive to disrupted clustering as raft proteins. 
These findings establish DHA as a potent disrupter of lipid raft clustering, and could 
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possibly yield functional differences in antigen presentation, compared to EPA, which 
should be explored in the future.
Raft clustering is dispersed on the sub-micron scale
! One of the significant questions we set out to answer was what effect the 
increased visible raft size has on molecular order and the nanoscale raft environment. 
Lipid rafts are defined as highly ordered in nature, yet n-3 PUFAs, DHA most of all, are 
highly disordered in nature, having a high degree of conformational mobility (105, 116). 
In Chapter 4, we used generalized polarization measurements to test molecular order 
with a unique florescent probe di-4-ANEPPDHQ. This probe is environmentally sensitive 
and displays an increased charge separation when excited in polar solvents (257, 258). 
The charge separation yields an increased dipole moment resulting in a red shift in its 
fluorescent emission. The calculation of membrane order is dependent on the change in 
water molecule penetration into the plasma membrane (259). Without a stimulus such 
as CTx-B cross-linking or immunological synapse formation, molecular order was 
decreased in B cells from the fish oil diet (Figure 4.3). Since solvent penetration is 
directly dependent on membrane packing order with this probe, it seems unlikely that 
this decrease in order was an artifact of just solvent penetration. Once a stimulus like 
the immunological synapse forms, DHA-PCs, unlike EPA-PCs, can interact with 
cholesterol, allowing for recovery in molecular order (256). This is exactly what we found 
in Figure 4.3. The change in order before and after cross-linking was significantly 
elevated with fish oil. 
! In Chapter 5 we demonstrate that although synapse formation occurs, the 
proteins vital for signaling have been displaced from the site of the immunological 
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synapse. MHC class II shows a trend toward nanoscale disrupted clustering, and a 
significant decrease in synapse localization (Figure 5.4). Although we did not measure 
molecular order at the synapse in B cells, there is evidence for n-3 PUFAs to actually 
enhance molecular order at the T cell side of the immunological synapse (140). Taken 
together, we propose a model to describe how DHA disrupts lipid raft clustering by 
creating a network of disrupted nanoscale size raft pieces, which DHA-PCs separate 
(Figure 6.1A). Disrupting raft clustering also frees GM1 clustering, which would allow for 
more binding of CTx-B (181). These pieces are now more easily extensively cross-
linked generating the increased visualized size. In a model of the immunological 
synapse, which has raft-like properties, a similar process would occur (Figure 6.2B). 
EPA and DHA-PEs have little affect on synapse organization. On the other hand, DHA-
PC in the synapse recruits cholesterol and slows MHC class II recruitment, disrupting 
synapse organization and, ultimately, T cell activation.
B cells are critical for autoimmune diseases
! We focused our studies on B cells, a cell type underrepresented in experiments 
with n-3 PUFAs, especially at the animal level. What we discovered in Chapter 5 was B 
cells are targetable in antigen presentation critical for subsequent CD4+ T cell activation. 
This is an important finding for autoimmune diseases such as rheumatoid arthritis, 
lupus, allograft rejection, and chronic allergic lung disease, where directed targeting of B  
cell antigen presentation would have clinical utility. In addition, n-3 PUFAs have been 
shown to promote a T helper 2 (Th2) response instead of a T helper 1 (Th1) response 
(260-264). Th1 cells produce pro-inflammatory cytokines IL-2, IFN-γ, and TNF-α, while 
Th2 cells produce anti-inflammatory cytokines IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 
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Figure 6.1: DHA disrupts lipid raft clustering and the immunological synapse. A) 
DHA-PC (red) can localize into clustered lipid rafts (yellow). This declusters the raft and 
when cross-linked the micron scale size appears larger. B) In B cells EPA/DHA can 
incorporate into the plasma membrane as PEs, but localize outside of the 
immunological synapse (yellow). DHA incorporated as PC can localize in the synapse 
along with cholesterol. This displaces signaling proteins such as MHC class II for the 
site of the immunological synapse, diminishing T cell activation. C) Overview of potential 
positive and negative affect of fish oil consumption on cell mediated and humoral 
immune response.
(265). Th2 cells are protective in diseases such as rheumatoid arthritis, type 1 diabetes, 
and multiple sclerosis, whereas Th1 cells are pathogenic (266). However, promoting 
Th2 immunity may not be universally beneficial. For example, in the case of lung 
inflammation disorders like allergic asthma, a Th2 response enhances progression of 
the disease (267-269). Though not fully investigated, this study demonstrates that fish 
oil in B cells may contribute to Th2/Th1 as evidenced by the reduced IL-2 secretion 
though disrupted antigen presentation (Figure 4.7B). While there are many important 
potential pathways to which fish oil can contribute, the implications of membrane 
disruption could lead to breakthroughs in other disease models. In Figure 6.1C is an 
outline describing these implications. A shift from Th1 to Th2 would decrease cell 
mediated immune response and increase the humoral immune response. This would 
not be universally beneficial for all diseases. In addition, studies looking at the other 
functions of B cells such as antibody production will further determine the utility of fish 
oil supplementation. 
Precaution for high doses of fish oil
! Once the mechanisms are better established, moving fish oil into the clinic will 
still have other considerations. One of these is the dosing necessary for clinical efficacy. 
The dose of fish oil used in many other studies varies widely, and dosing remains one of 
the larger challenges for strengthening our understanding of how fish oil exerts its 
effects (52). Our novel findings of body weight gain and energy expenditure reductions 
shown in Chapter 3 raise questions that must be addressed for proper clinical and 
dietary recommendations. Although fish oil is a source of EPA and DHA, these fatty 
acids only make up a modest percentage of the total fatty acid profile of fish oil. Analysis 
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of our fish oil diets shows a full fatty acid profile (Supplemental Table 2.1). In addition, 
there are some additional contaminants from consuming fish or fish oil including: 
methylmercury, dioxins, polychlorinated biphenyls, and organic pollutants from industrial 
processing (270). Monitoring the metabolic implications and dietary formulation for fish 
oil supplementation should be done in combination with any clinical studies moving 
forward. 
Conclusion
! Taken together, this work highlights the utility of fish oil, more specifically DHA, as 
a tool for disrupting plasma membrane lateral organization. We add to the biochemical 
understanding of how these fatty acids may disrupt various downstream signaling 
events and cell-cell interactions. It also emphasizes the importance of the plasma 
membrane as a target for suppressing other cellular functions mediated through lipid 
raft domains. Finally, these studies add B cells as key targets for suppression of antigen 
presentation in diseases such as rheumatoid arthritis.
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APPENDIX B: SUPPLEMENTAL TABLES AND FIGURES
Supplemental Table 2.1: Fatty acid analysis of experimental diets
Fatty Acid CD LF (n-3) PUFA HF (n-3) PUFA HF (n-6) PUFA
14:0 0.5 3.1 3.7 4.6
16:0 12.2 14.6 13.6 10.0 
16:1 0.1 4.3 4.9 0.1 
18:0 6.9 8.7 7.2 7.5 
18:1 trans 0.5 1.5 0.9 0.5 
18:1 cis 20.5 16.0 15.7 15.5 
18:2 (n-6) 48.0 13.6 12.1 58.3 
18:3 (n-3) 6.5 24.1 26.9 1.4 
20:5 (n-3) 0.0 4.4 5.0 0.1 
22:2 (n-6) 0.2 0.7 0.6 0.0 
22:5 (n-3) 0.1 0.8 0.8 0.0 
22:6 (n-3) 0.0 3.3 3.5 0.1 
∑SFA 20.4 27.0 25.0 22.6 
∑MUFA 23.0 24.3 24.0 17.1 
∑PUFA (n-3) 6.6 32.6 36.2 1.5 
∑PUFA (n-6) 50.0 16.1 14.8 58.7 
Fatty acids were extracted from the diets and analyzed with gas chromatography. 
Values are the percentage of total fatty acids. Values less than 0.5 are omitted for 
clarity.
B-2
Supplemental Figure 2.1: C16-Bodipy imaging studies. (A) EL4 cells were co-
stained with FAST-DiI and C16-Bodipy. The images are from a single z-stack used to 
calculate percent co- localization. The data are representative of 2 separate 
experiments. Co-localization is indicated by orange in the merge. (B) Average C16-
Bodipy intracellular and plasma membrane image intensity for EL4 cells treated 
overnight with BSA, OA, AA, EPA, and DHA. Data are means ± SEM, n= 4.
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Supplemental Figure 2.2
Supplemental Figure 2.2: MHC class I molecules were randomly distributed on 
EL4 cells. (A) Positive control before and after photobleaching images of EL4 cells 
stained with Cy3 (donor) and Cy5 (acceptor) labeled antibodies against MHC I. FRET 
efficiency increased by ~80%. (B) Sample data from a single experiment to show BSA 
or EPA treatment did not modifiy MHC I clustering since efficiency values did not 
increase with increasing donor:acceptor ratio. However, note EPA treatment lowered 
FRET values relative to BSA.
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Supplemental Figure 2.3: (n-3) PUFA diets did not increase FAST-DiI accumulation 
but HF (n-3) PUFA diet lowered C16-Bodipy uptake. (A) Fluorescent images of B 
cells isolated from C57BL/6 mice fed CD, HF (n-6), LF or HF (n-3) PUFA diets and 
stained with FAST-DiI. (B) Fluorescent C16-Bodipy images of B cells isolated from mice 
fed differing diets. Images are on a rainbow palette to discriminate differences in relative 
fluorescence intensity. Red and blue values, respectively, indicate high and low 
fluorescence intensity.
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B-5
Supplemental Figure 2.4: HF (n-3) PUFA diet disrupted lipid raft clustering. 
Fluorescent images of B cells isolated from C57BL/6 mice fed CD, HF (n-6), LF or HF 
(n-3) PUFA diets and stained for lipid rafts.
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Supplemental Table 4.1: Analysis of major fatty acids in mouse diets.
Fatty Acid Control Fish oil
14:0 0.2 6.7
16:0 11.7 24.6
16:1 0.1 13.1
18:0 5.2 6.3
18:1 trans 0.1 0.1
18:1 cis 21.6 12.6
18:2 (n-6) 53.7 3.1
18:3 (n-6) 0.3 0.6
18:3 (n-3) 6.9 1.7
20:4 (n-6) 0.0 1.3
20:5 (n-3) 0.0 15.7
22:5 (n-3) 0.0 0.3
22:6 (n-3) 0.0 11.2
∑SFA 17.2 37.6
∑MUFA 21.9 25.8
∑(n-6) PUFA 54.0 5.5
∑(n-3) PUFA 6.9 28.8
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Supplemental Figure 4.1: FO increased spleen size. (A) Body weights as a 
function of time for mice fed a control or FO diet. (B) Average daily food consumption. 
(C) Spleen weight after 3 weeks. Values are means ± SEM, n = 20-30 mice. Asterisks 
indicate different from control: **P< 0.01.
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Supplemental Figure 4.2
Supplemental Figure 4.2: Safflower oil-enriched diet did not increase lipid raft 
size. (A) TIRF microscopy images of B cell lipid rafts, induced upon cross-linking, from 
mice fed a control or safflower-enriched diet for 3 weeks. (B) Quantification of lipid raft 
size. (C) CTxB fluorescence intensity after cross-linking. Values are means ± SEM, n = 
4.
Supplemental Table 4.2: Cholesterol levels in DRM and DSM fractions from ex 
vivo and in vitro studies.  Mice were fed for 3 weeks a control or FO diet; EL4 cells 
were treated overnight with BSA, EPA, and DHA, as described in the Methods. 
Cholesterol values are fluorescence per µg of protein. Values are mean ± SEM from 4-5 
independent experiments. P values are for the DRM/DSM ratio. 
DRM DSM DRM/DSM p value
Control 419.8 ± 285.5 66.9 ± 6.1 7.1 ± 5.3
Fish Oil 305.6 ± 91.6 68.1 ± 3.5 4.6 ± 1.5 0.66
BSA 4962.6 ± 988.0 190.2 ± 31.0 27.2 ± 4.9
EPA 2390.2 ± 395.4 207.1 ± 25.9 12.7 ± 2.9 0.08
DHA 3425.4 ± 1490.9 204.5 ± 21.5 15.5 ± 5.7 0.08
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Supplemental Figure 4.3: FO had no impact on non-raft organization as measured 
by uptake of DiIC18. (A) Sample images of B cells from control and FO fed mice 
stained with DiIC18.  (B) Quantification of DiIC18 intensity. Values are means ± SEM, n = 
3-4. 
Control Fish oil
0
200
400
600
800
1000
In
te
ns
ity
Diet
A.
B.
Control Fish oil
Supplemental Figure 4.3
B-11
Supplemental Figure 4.4: EPA and DHA treatment had no effect on GM1 surface 
levels. GM1 surface levels (A) before and (B) after cross-linking rafts with CTxB upon 
treatment of EL4 cells with EPA or DHA relative to BSA.   Values are means ± SEM, n = 
4.
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Supplemental Figure 5.1
Supplemental Figure 5.1: Fish oil disrupts the B-T cell immunological synapse. A) 
Fluorescent intensity of MHC class II staining outside (Cell) and inside (Synapse) the 
immunological synapse for B cells from control (white) or fish oil (black) fed mice. B) 
Ratio of fluorescent intensity Synapse/Cell values for MHC class II staining. C) 
Fluorescent intensity of CD3ε and PKCθ staining outside (Cell) and inside (Synapse) 
the immunological synapse for B cells from control or fish oil fed mice. D) Ratio of 
fluorescent intensity Synapse/Cell values for CD3ε and PKCθ staining. Values are 
means ± SEM (n = 4 with 66 - 69 cells analyzed per diet). Asterisks indicate different 
from control: *P < 0.05; **P < 0.01.
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Supplemental Figure 5.1
Supplemental Figure 5.2: Pharmacological agents disrupt the B-T cell 
immunological synapse. A) Fluorescent intensity of MHC class II staining outside 
(Cell) and inside (Synapse) the immunological synapse for B cells from control (white) 
or MβCD (grey) and cytochalasin D (black) treatment. B) Ratio of fluorescent intensity 
Synapse/Cell values for MHC class II staining. C) Fluorescent intensity of CD3ε and 
PKCθ staining outside (Cell) and inside (Synapse) the immunological synapse. D) Ratio 
of fluorescent intensity Synapse/Cell values for CD3ε and PKCθ staining. Values are 
means ± SEM (n = 4 with 66 - 69 cells analyzed per diet). Asterisks indicate different 
from control: *P < 0.05; **P < 0.01.
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